CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10095098,100950985,5,F,,20180615,20140422,20180705,EXP,,CA-ABBVIE-14K-028-1226359-00,MYLAN,,54,YR,,M,Y,,,20180705,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,100950985,OT,,,100950985,8,2004,,,,100950985,1,Product used for unknown indication
10272117,102721174,4,F,20130815,20180614,20140702,20180724,PER,,US-009507513-1406USA009400,MERCK,,18,YR,,F,Y,,,20180724,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy;No adverse event;Normal newborn,,,,,,,,,,,102721174,1,Product used for unknown indication
10689255,106892552,2,F,,20180614,20150105,20180718,PER,,US-009507513-1412USA006214,MERCK,,18,YR,,F,Y,,,20180718,,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Pregnancy,,,,,,,,,,,106892552,1,Product used for unknown indication
10691044,106910442,2,F,,20180614,20150105,20180723,PER,,US-009507513-1412USA006569,MERCK,,34,YR,,F,Y,,,20180723,,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy,,,,,,,,,,,106910442,1,Product used for unknown indication
10725409,107254092,2,F,,20180802,20150121,20180809,EXP,,CA-ROCHE-1522668,ROCHE,PRIVACY P. UNKNOWN. UNKNOWN ?:?.,44,YR,,M,Y,,,20180809,,OT,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,107254092,HO,,,,,,,,,107254092,1,Depression
10725596,107255965,5,F,20141001,20180703,20150121,20180711,EXP,,CA-009507513-1501CAN005781,MERCK,,34,YR,,F,Y,,,20180711,,CN,CA,CA,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,107255965,OT,,,107255965,1,20140916,20140916,,,107255965,1,Hepatitis C
11094993,110949933,3,F,,20180911,20150506,20180918,PER,,US-JAZZ-2015-US-006432,JAZZ,,,,,M,Y,,,20180918,,,US,US,SUSTIVA,Drug hypersensitivity;Malabsorption;Psoriasis;Wrong technique in product usage process,,,,,110949933,1,201411,,,,110949933,1,Narcolepsy
11119425,111194253,3,F,,20180628,20150518,20180710,EXP,,ZA-CIPLA LTD.-2015ZA03809,CIPLA,"SOGBANMU OO, ADENIYI OV, FUENTES YO, TER GOON D.. VERY EARLY VIROLOGICAL FAILURE AND DRUG RESISTANCE MUTATIONS IN A WOMAN ON ANTIRETROVIRAL THERAPY IN EASTERN CAPE, SOUTH AFRICA: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2015?9:1 TO 9",,,,,Y,,,20180710,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Drug resistance;Virologic failure,111194253,OT,,,111194253,1,,201407,,,111194253,1,HIV infection
11258139,112581392,2,F,20150415,20180717,20150710,20180727,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-043114,BRISTOL MYERS SQUIBB,,32,YR,,M,Y,48.7,KG,20180727,,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Kaposi's sarcoma;Neutropenia,112581392,OT,,,112581392,1,20150221,20150610,,,112581392,1,Kaposi's sarcoma
11695249,116952493,3,F,20090930,20180823,20151103,20180903,EXP,FR-EMA-20130214-MMEVHUMANWT-150034270,FR-009507513-0906USA00645,MERCK,,19,YR,,F,Y,,,20180903,,CN,FR,FR,SUSTIVA,Caesarean section;Drug ineffective;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive;Unintended pregnancy,116952493,OT,,,116952493,1,20080215,,,,116952493,1,HIV infection
11705185,117051852,2,F,200805,20180806,20151106,20180814,EXP,,GB-009507513-0807USA00501,MERCK,,32,YR,,F,Y,57,KG,20180814,,CN,GB,GB,SUSTIVA,Drug interaction;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,117051852,OT,,,117051852,2,2006,,,,117051852,1,HIV test
11721175,117211752,2,F,20121128,20180703,20151110,20180713,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-17392481,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,2.88,KG,20180713,,OT,BR,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,117211752,OT,,,117211752,1,20120521,20120611,,,117211752,1,Product used for unknown indication
11744738,117447385,5,F,2008,20180808,20151116,20180817,EXP,,GB-009507513-1001USA00481,MERCK,,33,YR,,F,Y,,,20180817,,OT,GB,GB,EFAVIRENZ.,Labelled drug-drug interaction medication error;Normal newborn;Pregnancy with implant contraceptive,117447385,OT,,,117447385,2,20040811,20070716,,,117447385,1,HIV infection
11816005,118160055,5,F,,20180828,20151209,20180903,EXP,,US-009507513-1011USA03112,MERCK,,35,YR,,F,Y,,,20180903,,OT,GB,US,EFAVIRENZ.,Abortion induced;Drug interaction;Pregnancy with implant contraceptive,118160055,OT,,,,,,,,,118160055,1,Antiretroviral therapy
11868354,118683547,7,F,20001221,20180921,20151224,20180930,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11527520,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20180930,,OT,FR,FR,EFAVIRENZ.,Gestational diabetes;Normal newborn;Pregnancy,118683547,OT,,,118683547,1,19970902,,,,118683547,1,Antiretroviral therapy
11881235,118812353,3,F,20140220,20180614,20151231,20180717,PER,,US-009507513-1512USA007300,MERCK,,29,YR,,F,Y,,,20180717,,CN,US,US,EFAVIRENZ.,Maternal exposure during pregnancy;No adverse event;Normal newborn;Off label use,,,,,,,,,,,118812353,1,Antiretroviral therapy
11883063,118830636,6,F,,20180703,20151231,20180716,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-090408,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20180716,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,118830636,OT,,,118830636,1,2007,,,,118830636,1,HIV infection
12642922,126429226,6,F,,20180628,20160811,20180711,EXP,,US-CIPLA LTD.-2016US17002,CIPLA,,,,,,Y,,,20180711,,OT,US,US,EFAVIRENZ.,Acute kidney injury;Drug interaction;Nephropathy toxic,126429226,HO,,,,,,,,,126429226,1,HIV infection
12887926,128879262,2,F,,20180718,20161027,20180730,EXP,,US-CIPLA LTD.-2016US19822,CIPLA,"FONG PS, FLYNN DM, EVANS CD, KORTHUIS PT. INTEGRASE STRAND TRANSFER INHIBITOR?ASSOCIATED DIABETES MELLITUS: A CASE REPORT. INT J STD AIDS. 2016",,,,,Y,,,20180730,,OT,US,US,EFAVIRENZ.,Diabetes mellitus,128879262,OT,,,,,,,,,,,
12953684,129536844,4,F,20161102,20180809,20161117,20180820,EXP,,MW-GILEAD-2016-0242786,GILEAD,,35,YR,A,M,Y,60,KG,20180820,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,129536844,HO,,,129536844,1,20150714,20160926,,,129536844,1,Kaposi's sarcoma AIDS related
13014538,130145387,7,F,,20180829,20161209,20180907,EXP,,PHHY2015BR064616,NOVARTIS,,,,,F,Y,54,KG,20180907,,MD,BR,BR,EFAVIRENZ.,Alopecia;Amenorrhoea;Blood iron increased;Chills;Diarrhoea;Dizziness;Drug intolerance;Dysphagia;Haemoglobin abnormal;Inappropriate schedule of drug administration;Malaise;Nausea;Poisoning;Retching;Serum ferritin abnormal;Serum ferritin decreased;Serum ferritin increased;Vomiting;Weight increased;Wrong technique in product usage process,130145387,OT,,,,,,,,,130145387,1,Haemoglobinopathy
13258114,132581142,2,F,20160819,20180808,20170221,20180820,EXP,,MW-GILEAD-2017-0258042,GILEAD,,35,YR,A,M,Y,60,KG,20180820,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Kaposi's sarcoma,132581142,OT,,,132581142,1,20150715,20170206,,,132581142,1,Acquired immunodeficiency syndrome
13274215,132742156,6,F,,20180720,20170227,20180730,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-015407,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20180730,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,132742156,OT,,,132742156,1,200909,,,,132742156,1,HIV infection
13278460,132784608,8,F,,20180823,20170228,20180831,EXP,,FR-009507513-1702FRA008506,MERCK,"RUELLAN AL, VEYRAC G, BRUNET?CARTIER C, JARNET L, JOLLIET P.. ETONOGESTREL AND EFAVIRENZ DRUG INTERACTION: RISK OF CONTRACEPTION INEFFICACY. FUNDAMENTAL AND CLINICAL PHARMACOLOGY. 2016?30 SUPPL 1:50",32,YR,,F,Y,,,20180831,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,132784608,OT,,,132784608,1,201007,,,,132784608,1,Contraception
13335985,133359853,3,F,20150430,20180711,20170314,20180724,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-021688,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20180724,,CN,FR,FR,SUSTIVA,Gestational hypertension;Headache;Live birth;Maternal exposure during pregnancy;Metrorrhagia;Placental disorder;Premature labour;Product use issue;Streptococcus test positive,133359853,OT,,,,,,,,,133359853,1,HIV infection
13335986,133359865,5,F,20150224,20180711,20170314,20180724,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-018934,BRISTOL MYERS SQUIBB,,,,,,Y,2.64,KG,20180724,,OT,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction,133359865,OT,,,,,,,,,133359865,1,Product used for unknown indication
13339761,133397617,7,F,,20180824,20170315,20180904,EXP,,FR-009507513-1702FRA008692,MERCK,"RUELLAN AL, VEYRAC G, BRUNET?CARTLER C, JARNET L, JOLLIET P. ETONOGESTREL AND EFAVIRENZ DRUG INTERACTION: RISK OF CONTRACEPTION INEFFICACY. FUNDAMENTAL AND CLINICAL PHARMACOLOGY. 2016?30 SUPPL (1):50",28,YR,,F,Y,,,20180904,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,133397617,OT,,,133397617,2,201206,,,,133397617,1,HIV infection
13521928,135219282,2,F,,20180824,20170508,20180907,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2017065893,VIIV,UNK. UNK. UNK. UNK?UNK:UNK,52,YR,,M,Y,,,20180907,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,135219282,OT,,,,,,,,,135219282,1,HIV infection
13522216,135222162,2,F,,20180824,20170508,20180907,EXP,,CA-GLAXOSMITHKLINE-CA2017065893,GLAXOSMITHKLINE,UNK. UNK. UNK. UNK?UNK:UNK,52,YR,,M,Y,,,20180907,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,135222162,OT,,,,,,,,,135222162,1,HIV infection
13948042,139480423,3,F,,20180718,20170908,20180727,PER,,US-PFIZER INC-2017391008,PFIZER,,58,YR,,M,Y,,,20180727,,MD,US,US,SUSTIVA,Drug hypersensitivity;Rash,,,,,,,,,,,,,
13984466,139844667,7,F,20170901,20171009,20170918,20180706,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-083133,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180706,,OT,BR,BR,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery;Urinary tract infection,139844667,OT,,,139844667,1,20170629,20170907,,,139844667,1,HIV infection
14111106,141111064,4,F,20150608,20180713,20171020,20180726,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017GSK161303,VIIV,,0,DY,,M,Y,3,KG,20180726,,CN,US,FR,SUSTIVA,Atrophy;Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Small for dates baby,141111064,CA,,,141111064,3,20150608,20150608,,,141111064,1,HIV infection
14111227,141112274,4,F,20150608,20180713,20171020,20180726,EXP,,FR-GLAXOSMITHKLINE-FR2017GSK161303,GLAXOSMITHKLINE,,0,DY,,M,Y,3,KG,20180726,,CN,US,FR,SUSTIVA,Atrophy;Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Small for dates baby,141112274,CA,,,141112274,3,20150608,20150608,,,141112274,1,HIV infection
14132073,141320734,4,F,20150608,20180711,20171027,20180726,EXP,,FR-AUROBINDO-AUR-APL-2017-42194,AUROBINDO,,0,DY,,M,Y,2.64,KG,20180726,,CN,US,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Muscle atrophy;Small for dates baby,141320734,CA,,,141320734,5,20150608,20150608,,,141320734,1,HIV infection
14147931,141479312,2,F,,20180628,20171031,20180706,EXP,,CA-GILEAD-2017-0301425,GILEAD,,,,N,,Y,,,20180706,,OT,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,141479312,CA,,,,,,,,,141479312,1,Prophylaxis against HIV infection
14165463,141654638,8,F,201404,20180814,20171107,20180829,EXP,,IT-AUROBINDO-AUR-APL-2017-43260,AUROBINDO,,27,YR,,F,Y,,,20180829,,OT,IT,IT,Efavirenz Film Coated Tablets,Drug resistance;End stage renal disease;Pathogen resistance;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,141654638,OT,,,141654638,6,201505,,,,141654638,1,Antiretroviral therapy
14221665,142216654,4,F,20170823,20180718,20171124,20180725,EXP,,PHHY2017CO172327,NOVARTIS,,57,YR,,M,Y,54,KG,20180725,,CN,COUNTRY NOT SPECIFIED,CO,EFAVIRENZ.,Arthralgia;Decreased immune responsiveness;Inappropriate schedule of drug administration;Platelet count decreased,142216654,OT,,,142216654,1,20110317,,,,142216654,1,Chronic myeloid leukaemia
14246609,142466095,5,F,,20180906,20171204,20180919,EXP,,GB-AUROBINDO-AUR-APL-2017-43959,AUROBINDO,,85,YR,,M,Y,,,20180919,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142466095,OT,,,,,,,,,142466095,1,Cardiovascular event prophylaxis
14254383,1425438310,10,F,,20180919,20171205,20180920,EXP,,GB-TEVA-2017-GB-828487,TEVA,,85,YR,,M,Y,,,20180920,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,1425438310,OT,,,,,,,,,1425438310,1,Cardiovascular event prophylaxis
14265127,142651272,2,F,2015,20180817,20171208,20180827,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2017GSK177731,VIIV,,56,YR,,M,Y,57,KG,20180827,,MD,FR,FR,SUSTIVA,General physical health deterioration;Hypermetabolism;Pulmonary mass;Virologic failure,142651272,HO,,,142651272,1,,20151117,,,142651272,1,HIV infection
14329471,143294714,4,F,20150224,20180803,20171227,20180809,EXP,,FR-ASTELLAS-2017US055480,ASTELLAS,,,,I,M,Y,3,KG,20180809,,OT,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Muscle atrophy;Small for dates baby,143294714,CA,,,143294714,3,20150608,20150608,,,143294714,1,Foetal exposure during pregnancy
14330230,143302302,2,F,20150608,20180712,20171227,20180723,EXP,,FR-LEO PHARMA-306601,LEO PHARM,,0,DY,,M,Y,2.64,KG,20180723,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Muscle atrophy;Small for dates baby,143302302,CA,,,143302302,5,20150608,20150608,,,143302302,1,Product used for unknown indication
14344346,143443462,2,F,,20180704,20180102,20180713,EXP,,GB-MYLANLABS-2017M1083674,MYLAN,,,,,,Y,,,20180713,,OT,GB,GB,EFAVIRENZ.,Disturbance in attention;Enuresis;Fatigue;Gynaecomastia;Headache;Hypercholesterolaemia;Mood altered;Psychotic disorder;Sleep disorder;Stevens-Johnson syndrome;Virologic failure,143443462,OT,,,,,,,,,143443462,1,Product used for unknown indication
14363782,143637824,4,F,201404,20180703,20180108,20180712,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-098391,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20180712,,CN,IT,IT,EFAVIRENZ.,Drug resistance;End stage renal disease;Prescribed overdose;Treatment noncompliance;Viral mutation identified;Virologic failure,143637824,OT,,,,,,,,,143637824,1,HIV infection
14553441,145534416,6,F,20171107,20180805,20180220,20180813,EXP,GB-MHRA-EYC 00171403,GB-TEVA-2018-GB-857839,TEVA,,47,YR,,F,Y,,,20180813,,MD,GB,GB,EFAVIRENZ.,Acute hepatic failure;Product substitution issue,145534416,HO,,,145534416,1,20170501,20171216,,,145534416,1,HIV infection
14568246,145682462,2,F,20180209,20180821,20180223,20180831,EXP,,BR-CIPLA LTD.-2018BR06248,CIPLA,,,,,,Y,,,20180831,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Abortion spontaneous;Contraindicated product administered;Exposure during pregnancy,145682462,OT,,,145682462,1,20180103,20180103,,,145682462,1,HIV infection
14596238,145962385,5,F,,20180720,20180303,20180803,EXP,,FR-AUROBINDO-AUR-APL-2018-010672,AUROBINDO,,32,YR,,F,Y,,,20180803,,OT,FR,FR,Efavirenz Film Coated Tablets,Abortion induced;Drug interaction;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue;Unwanted pregnancy,145962385,OT,,,145962385,1,20090901,,,,145962385,1,HIV infection
14599811,145998112,2,F,,20180719,20180305,20180726,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018031666,VIIV,ESTEVES T.. MATERNAL DRUG USE DURING PREGNANCY AND INFANCY ?THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH.. REVISTA PORTUGUESA DE CLINICA GERAL.. 2011?27::458?64,27,YR,,F,Y,,,20180726,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,145998112,OT,,,145998112,3,2007,,,,145998112,1,HIV infection
14599813,145998132,2,F,,20180719,20180305,20180726,EXP,,PT-GLAXOSMITHKLINE-PT2018031666,GLAXOSMITHKLINE,ESTEVES T.. MATERNAL DRUG USE DURING PREGNANCY AND INFANCY ?THE IMPORTANCE OF A MULTIDISCIPLINARY APPROACH.. REVISTA PORTUGUESA DE CLINICA GERAL.. 2011?27::458?64,27,YR,,F,Y,,,20180726,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,145998132,OT,,,145998132,3,2007,,,,145998132,1,HIV infection
14610366,146103662,2,F,20060602,20180712,20180307,20180724,EXP,CA-HEALTH CANADA-E2B_01366855,CA-ALLERGAN-1812285US,ALLERGAN,,44,YR,,M,Y,,,20180724,,OT,CA,CA,SUSTIVA,Anxiety;Condition aggravated;Contraindicated product administered;Depression;Depression suicidal;Depressive symptom;Drug interaction;Off label use;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,146103662,HO,,,146103662,2,20070729,20060602,,,146103662,1,Psychotic disorder
14651092,146510925,5,F,,20180724,20180316,20180730,EXP,FR-EMA-20170316-SROYP-090824780,FR-GILEAD-2016-0216060,GILEAD,,32,YR,A,F,Y,,,20180730,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,146510925,OT,,,146510925,7,201007,,,,146510925,1,HIV infection
14654041,1465404115,15,F,,20180704,20180319,20180716,EXP,,PHHY2018IE041144,NOVARTIS,"BRODERICK C, QUINLAN C, GULMANN C, O^KANE M.. RECALCITRANT CUTANEOUS SARCOIDOSIS, WITH RESPONSE TO DAYLIGHT PHOTODYNAMIC THERAPY.. 75TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2017?76(6SUPPL1):AB216",,,,,Y,,,20180716,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective;Leukopenia;Off label use;Product use in unapproved indication;Skin atrophy,1465404115,OT,,,,,,,,,1465404115,1,Sarcoidosis
14715667,147156673,3,F,201607,20180823,20180404,20180911,PER,,US-VIFOR (INTERNATIONAL) INC.-VIT-2016-08052,VIFOR,,60,YR,,M,Y,,,20180911,,CN,US,US,SUSTIVA,Burning sensation;Drug dose omission;Rash pruritic;Skin discolouration;Skin haemorrhage,,,,,147156673,1,20160727,,,,147156673,1,Hyperkalaemia
14750868,147508682,2,F,,20180909,20180412,20180921,EXP,,DE-AUROBINDO-AUR-APL-2017-47615,AUROBINDO,,43,YR,,F,Y,,,20180921,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,147508682,OT,,,,,,,,,147508682,1,Product used for unknown indication
14767950,147679502,2,F,,20180731,20180417,20180809,EXP,,ZA-MYLANLABS-2018M1024536,MYLAN,,,,,F,Y,59,KG,20180809,,MD,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Seizure;Treatment noncompliance,147679502,OT,,,147679502,1,20170117,,,,147679502,1,Tuberculosis
14813041,148130412,2,F,,20180622,20180426,20180706,EXP,,US-CIPLA (EU) LIMITED-2018US16704,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016?1?21",,,,,Y,,,20180706,,OT,US,US,EFAVIRENZ.,Renal failure,148130412,OT,,,,,,,,,148130412,1,HIV infection
14818099,148180992,2,F,,20180622,20180427,20180706,EXP,,US-CIPLA (EU) LIMITED-2018US16705,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016?1?21",,,,,Y,,,20180706,,OT,US,US,EFAVIRENZ.,Glomerulonephritis acute,148180992,OT,,,,,,,,,148180992,1,HIV infection
14819152,148191522,2,F,,20180622,20180427,20180706,EXP,,US-CIPLA (EU) LIMITED-2018US16723,CIPLA,"SAX PE, DEJESUS E, MILLS A, ZOLOPA A, COHEN C, WOHL D ET AL. CO?FORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR VERSUS CO?FORMULATED EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR FOR INITIAL TREATMENT OF HIV?1 INFECTION:A RANDOMISED, DOUBLE?BLIND, PHASE 3 TRIAL, ANALYSIS OF RESULTS AFTER 48 WEEKS. LANCET. 2012?379:2439?2448",,,,,Y,,,20180706,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Metastatic neoplasm,148191522,DE,,,,,,,,,148191522,1,HIV infection
14819154,148191542,2,F,,20180622,20180427,20180706,EXP,,US-CIPLA (EU) LIMITED-2018US16702,CIPLA,"BEDIMO R, ROSENBLATT L AND MYERS J. SYSTEMATIC REVIEW OF RENAL AND BONE SAFETY OF THE ANTIRETROVIRAL REGIMEN EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HIV INFECTION. HIV CLINICAL TRIALS. 2016?1?21",,,,,Y,,,20180706,,OT,US,US,EFAVIRENZ.,Nephrolithiasis,148191542,OT,,,,,,,,,148191542,1,HIV infection
14858559,148585592,2,F,,20180614,20180508,20180723,PER,,US-009507513-1804USA011853,MERCK,,18,YR,,F,Y,,,20180723,,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;No adverse event,,,,,148585592,1,201012,,,,,,
14869524,148695244,4,F,2002,20180820,20180509,20180827,EXP,,PT-JNJFOC-20180508029,JANSSEN,"MARTINS S, QUINAZ C, XARA S, VASCONCELOS O, VICENTE P, SARMENTO?CASTRO R. AIDS ?RELATED PRIMARY PULMONARY LYMPHOMA. REVISTA PORTUGUESA DE DOENCAS INFECCIOSAS. 2017?13 (3):142?5.",55,YR,A,M,Y,,,20180827,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,148695244,DE,,,148695244,3,1997,,,,148695244,1,HIV infection
14881427,148814272,2,F,,20180614,20180511,20180723,PER,,US-009507513-1805USA003216,MERCK,,20,YR,,F,Y,,,20180723,,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;No adverse event,,,,,,,,,,,,,
14881855,148818553,3,F,,20180614,20180511,20180806,PER,,US-009507513-1805USA003795,MERCK,,30,YR,,F,Y,,,20180806,,CN,US,US,efavirenz (+) emtricitabine (+) tenofovir disoproxil fumarate,Maternal exposure during pregnancy,,,,,,,,,,,148818553,1,Antiretroviral therapy
14894776,148947763,3,F,2002,20180625,20180515,20180706,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-041488,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,,,20180706,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,148947763,HO,,,148947763,5,1997,,,,148947763,1,HIV infection
14895215,148952152,2,F,,20180703,20180515,20180716,EXP,GB-FERRINGPH-2017FE05839,GB-ACCORD-066886,ACCORD,,,,,,Y,,,20180716,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,148952152,OT,,,,,,,,,148952152,1,Cardiovascular event prophylaxis
14900505,149005053,3,F,2002,20180816,20180516,20180830,EXP,,PT-AUROBINDO-AUR-APL-2018-025856,AUROBINDO,,55,YR,,M,Y,,,20180830,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Drug ineffective;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,149005053,OT,,,149005053,1,1997,2010,,,149005053,1,HIV infection
14911344,149113443,3,F,,20180810,20180518,20180822,EXP,,ZA-CIPLA (EU) LIMITED-2018ZA17895,CIPLA,,,,,,Y,,,20180822,,OT,US,ZA,EFAVIRENZ.,Antiviral drug level above therapeutic;Generalised tonic-clonic seizure;Postictal state;Urinary incontinence,149113443,OT,,,,,,,,,149113443,1,Perinatal HIV infection
14915819,149158192,2,F,,20180712,20180518,20180724,EXP,,US-GILEAD-2018-0339050,GILEAD,,73,YR,E,M,Y,,,20180724,,MD,US,US,EFAVIRENZ.,Drug interaction;Fanconi syndrome acquired,149158192,OT,,,,,,,,,149158192,1,Hepatitis C
14929705,149297052,2,F,2007,20180809,20180523,20180817,EXP,,US-ASTRAZENECA-2018SE65525,ASTRAZENECA,,58,YR,,F,Y,49,KG,20180817,,,US,US,EFAVIRENZ.,Acute kidney injury;Anxiety;Chronic kidney disease;Renal failure,149297052,OT,,,149297052,1,20070101,20161011,,,149297052,1,Dyspepsia
14942273,149422735,5,F,20180512,20180830,20180528,20180906,EXP,,UG-CIPLA LTD.-2018UG18131,CIPLA,,,,,,Y,,,20180906,,OT,UG,UG,EFAVIRENZ.,Death;Myelitis transverse,149422735,OT,,,149422735,1,20180420,20180424,,,149422735,1,Meningitis cryptococcal
14961417,149614172,2,F,,20180823,20180601,20180823,EXP,,FR-MACLEODS PHARMACEUTICALS US LTD-MAC2018013928,MACLEODS,,,,,,Y,,,20180823,,CN,FR,FR,EFAVIRENZ.,Fanconi syndrome;Nephropathy toxic;Renal tubular dysfunction,149614172,OT,,,,,,,,,149614172,1,Antiretroviral therapy
14961910,149619103,3,F,,20180814,20180601,20180822,EXP,,TZ-CIPLA (EU) LIMITED-2018TZ17784,CIPLA,"MAPESI H, LETANG E, RAMIREZ A, TANNER M, HATZ C.. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH DERMATOPHYTOSES IN TWO HIV?1 POSITIVE PATIENTS IN RURAL TANZANIA: A CASE REPORT. BMC INFECTIOUS DISEASES. 2016?16:495:1 TO 5",,,,,Y,,,20180822,,OT,TZ,TZ,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Immune reconstitution inflammatory syndrome;Tinea infection,149619103,OT,,,,,,,,,149619103,1,HIV infection WHO clinical stage II
14980065,149800652,2,F,20180524,20180704,20180606,20180709,EXP,,ZA-JNJFOC-20180602444,JANSSEN,,48,YR,A,M,Y,50,KG,20180709,,MD,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR,Disseminated tuberculosis,149800652,DE,,,149800652,1,20151104,2016,,,149800652,1,Pulmonary tuberculosis
14981967,149819672,2,F,,20180725,20180607,20180803,EXP,,US-CIPLA LTD.-2018US18954,CIPLA,,,,,,Y,,,20180803,,OT,US,US,EFAVIRENZ.,Acute kidney injury,149819672,OT,,,,,,,,,149819672,1,Product used for unknown indication
14983919,149839193,3,F,,20180907,20180607,20180913,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018GSK100503,VIIV,,48,YR,,F,Y,,,20180913,,MD,FR,FR,SUSTIVA,Drug interaction;Tuberculosis,149839193,OT,,,149839193,1,20160528,20160704,,,149839193,1,HIV infection
14986841,149868412,2,F,,20180903,20180608,20180918,EXP,,ZA-ALKEM LABORATORIES LIMITED-ZA-ALKEM-2018-03723,ALKEM,"PRIETO LM, SANTIAGO B, ROSAL TD, CARAZO B, ET AL.. LINEZOLID?CONTAINING TREATMENT REGIMENS FOR TUBERCULOSIS IN CHILDREN. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2018?1?24",6,YR,,F,Y,,,20180918,,MD,ES,ZA,EFAVIRENZ.,Drug resistance;Lactic acidosis;Pancreatitis,149868412,OT,,,,,,,,,149868412,1,Tuberculosis
14992195,149921952,2,F,20160228,20180625,20180608,20180703,EXP,,GH-GILEAD-2018-0343050,GILEAD,,,,A,F,Y,,,20180703,,OT,GH,GH,EFAVIRENZ.,Psychotic disorder,149921952,OT,,,149921952,3,20160226,20160309,,,149921952,1,HIV infection
14992306,149923064,4,F,,20180626,20180608,20180703,EXP,,BR-ABBVIE-18S-020-2379837-00,ABBVIE,,,,,F,Y,2.25,KG,20180703,,OT,BR,BR,LAMIVUDINE+EFAVIRENZ+TENOFO,Congenital genital malformation female;Foetal exposure during pregnancy,149923064,CA,,,,,,,,,149923064,1,Maternal exposure timing unspecified
15016011,150160114,4,F,20180603,20180905,20180615,20180913,EXP,,FR-BEH-2018091357,CSL BEHRING,,59,YR,A,M,Y,,,20180913,,CN,FR,FR,EFAVIRENZ.,Peripheral ischaemia,150160114,DS,,,150160114,1,20180501,20180604,,,150160114,1,Factor IX deficiency
15037588,150375882,2,F,20171227,20180823,20180620,20180831,EXP,,ZA-MYLANLABS-2018M1043162,MYLAN,,22,YR,,M,Y,42,KG,20180830,,MD,ZA,ZA,EFAVIRENZ.,Bundle branch block left;Chest pain;Incorrect drug administration duration,150375882,LT,,,150375882,1,20170330,20171227,,,150375882,1,Pulmonary tuberculosis
15050521,150505211,1,I,,20180608,20180622,20180622,EXP,,GB-MYLANLABS-2018M1041938,MYLAN,,57,YR,,M,Y,,,20180615,,CN,GB,GB,EFAVIRENZ.,Prostate cancer,150505211,OT,,,,,,,,,150505211,1,Product used for unknown indication
15060764,150607641,1,I,20180115,20180613,20180625,20180625,EXP,,CA-MYLANLABS-2018M1043961,MYLAN,,44,YR,,M,Y,61,KG,20180620,,PH,CA,CA,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Drug ineffective,150607641,OT,,,150607641,1,20171117,,,,150607641,1,HIV infection
15095440,150954405,5,F,20171006,20180829,20180702,20180904,EXP,,GB-GILEAD-2018-0347475,GILEAD,,43,YR,A,F,Y,,,20180904,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,150954405,OT,,,150954405,1,20171006,,,,150954405,1,HIV infection
15101395,151013951,1,I,,20180629,20180703,20180703,EXP,GB-MHRA-EYC 00181171,GB-VIIV HEALTHCARE LIMITED-GB2018116277,VIIV,,44,YR,,,Y,,,20180703,,CN,GB,GB,EFAVIRENZ.,Death,151013951,OT,,,,,,,,,151013951,1,HIV infection
15101516,151015161,1,I,,20180629,20180703,20180703,EXP,GB-MHRA-EYC 00181171,GB-GLAXOSMITHKLINE-GB2018116277,GLAXOSMITHKLINE,,44,YR,,,Y,,,20180703,,CN,GB,GB,EFAVIRENZ.,Death,151015161,DE,,,,,,,,,151015161,1,HIV infection
15103404,151034041,1,I,20180625,20180625,20180703,20180703,EXP,,BR-MYLANLABS-2018M1048343,MYLAN,,30,YR,,F,Y,,,20180703,,OT,BR,BR,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Abortion spontaneous;Maternal exposure during pregnancy,151034041,OT,,,151034041,1,20150110,,,,151034041,1,HIV infection
15104645,151046451,1,I,20180217,20180625,20180703,20180703,EXP,,PHHY2018LS032604,NOVARTIS,,37,YR,,M,Y,45,KG,20180703,,CN,LS,LS,TENOFOVIR + LAMIVUDINE + EFAVIRENZ,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood alkaline phosphatase increased;Blood bilirubin increased;Drug-induced liver injury;Gamma-glutamyltransferase increased;Nausea;Seizure;Vomiting,151046451,OT,,,151046451,1,20180219,20180605,,,151046451,1,Pulmonary tuberculosis
15109396,151093963,3,F,,20180710,20180705,20180720,EXP,,GB-HETERO CORPORATE-HET2018GB00592,HETERO,,,,,M,Y,,,20180720,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Maternal drugs affecting foetus;Trisomy 18,151093963,DE,,,151093963,1,,20180205,,,151093963,1,HIV infection
15112110,151121104,4,F,20171006,20180710,20180705,20180720,EXP,,GB-GILEAD-2018-0347708,GILEAD,,,,,M,Y,,,20180720,,CN,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,151121104,OT,,,151121104,1,20171006,20180205,,,151121104,1,HIV infection
15112462,151124621,1,I,,20180627,20180705,20180705,EXP,,IT-GILEAD-2018-0347888,GILEAD,,,,A,,Y,,,20180705,,OT,COUNTRY NOT SPECIFIED,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiotoxicity,151124621,OT,,,,,,,,,151124621,1,HIV infection
15114149,151141494,4,F,20171006,20180712,20180706,20180726,EXP,,GB-AUROBINDO-AUR-APL-2018-033634,AUROBINDO,,,,,M,Y,,,20180726,,OT,GB,GB,Efavirenz Film?coated Tablet,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,151141494,OT,,,151141494,1,20171006,20180205,,,151141494,1,HIV infection
15115814,151158142,2,F,,20180716,20180706,20180727,EXP,,GB-MYLANLABS-2018M1048354,MYLAN,,,,,M,Y,,,20180727,,OT,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,151158142,CA,,,,,,,,,151158142,1,Product used for unknown indication
15118575,151185751,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-059819,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,IT,IT,EFAVIRENZ.,Death;Neurotoxicity;Toxicity to various agents,151185751,DE,,,,,,,,,151185751,1,HIV infection
15119112,151191121,1,I,,20180624,20180709,20180709,EXP,,IT-AUROBINDO-AUR-APL-2018-034732,AUROBINDO,,,,A,,Y,,,20180709,,OT,IT,IT,EFAVIRENZ FILM COATED TABLETS,Cardiotoxicity;Toxicity to various agents,151191121,OT,,,,,,,,,151191121,1,HIV infection
15120220,151202201,1,I,,20180624,20180709,20180709,EXP,,IT-AUROBINDO-AUR-APL-2018-034733,AUROBINDO,,,,A,,Y,,,20180709,,OT,IT,IT,EFAVIRENZ FILM COATED TABLETS,Drug intolerance;Lipodystrophy acquired,151202201,OT,,,,,,,,,151202201,1,HIV infection
15120221,151202211,1,I,,20180624,20180709,20180709,EXP,,IT-AUROBINDO-AUR-APL-2018-034730,AUROBINDO,,,,A,,Y,,,20180709,,OT,IT,IT,EFAVIRENZ FILM COATED TABLETS,Neurotoxicity;Toxicity to various agents,151202211,OT,,,,,,,,,151202211,1,HIV infection
15120227,151202271,1,I,,20180624,20180709,20180709,EXP,,IT-AUROBINDO-AUR-APL-2018-034731,AUROBINDO,,,,A,,Y,,,20180709,,OT,IT,IT,EFAVIRENZ FILM COATED TABLETS,Hepatotoxicity;Toxicity to various agents,151202271,OT,,,,,,,,,151202271,1,HIV infection
15120389,151203891,1,I,,20171023,20180709,20180709,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2017203843,VIIV,"BERARD A, ET AL.. ANTIRETROVIRAL COMBINATION USE DURING PREGNANCYAND THE RISK OF MAJOR CONGENITAL MALFORMATIONS.. AIDS.. 2017?31:2267?2277",,,N,,Y,,,20180709,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,151203891,OT,,,,,,,,,151203891,1,HIV infection
15120396,151203961,1,I,,20171023,20180709,20180709,EXP,,CA-GLAXOSMITHKLINE-CA2017203843,GLAXOSMITHKLINE,"BERARD A, ET AL.. ANTIRETROVIRAL COMBINATION USE DURING PREGNANCYAND THE RISK OF MAJOR CONGENITAL MALFORMATIONS.. AIDS.. 2017?31:2267?2277",,,N,,Y,,,20180709,,OT,CA,CA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,151203961,OT,,,,,,,,,151203961,1,HIV infection
15123441,151234411,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064192,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151234411,OT,,,,,,,,,151234411,1,HIV infection
15123442,151234421,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064194,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151234421,OT,,,,,,,,,151234421,1,HIV infection
15123443,151234431,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064195,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151234431,OT,,,,,,,,,151234431,1,HIV infection
15123453,151234531,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064220,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Cardiotoxicity,151234531,OT,,,,,,,,,151234531,1,HIV infection
15123455,151234551,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064221,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234551,OT,,,,,,,,,151234551,1,HIV infection
15123467,151234671,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064225,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234671,OT,,,,,,,,,151234671,1,HIV infection
15123468,151234681,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064244,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234681,OT,,,,,,,,,151234681,1,HIV infection
15123469,151234691,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064224,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234691,OT,,,,,,,,,151234691,1,HIV infection
15123470,151234701,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064228,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234701,OT,,,,,,,,,151234701,1,HIV infection
15123471,151234711,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064226,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234711,OT,,,,,,,,,151234711,1,HIV infection
15123475,151234751,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064240,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234751,OT,,,,,,,,,151234751,1,HIV infection
15123476,151234761,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064223,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234761,OT,,,,,,,,,151234761,1,HIV infection
15123479,151234791,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064222,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234791,OT,,,,,,,,,151234791,1,HIV infection
15123480,151234801,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064227,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234801,OT,,,,,,,,,151234801,1,HIV infection
15123481,151234811,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064239,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234811,OT,,,,,,,,,151234811,1,HIV infection
15123482,151234821,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064243,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234821,OT,,,,,,,,,151234821,1,HIV infection
15123483,151234831,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064242,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234831,OT,,,,,,,,,151234831,1,HIV infection
15123484,151234841,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064238,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234841,OT,,,,,,,,,151234841,1,HIV infection
15123485,151234851,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064241,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234851,OT,,,,,,,,,151234851,1,HIV infection
15123491,151234911,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064233,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234911,OT,,,,,,,,,151234911,1,HIV infection
15123492,151234921,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064237,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234921,OT,,,,,,,,,151234921,1,HIV infection
15123493,151234931,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064245,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151234931,OT,,,,,,,,,151234931,1,HIV infection
15123494,151234941,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064230,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234941,OT,,,,,,,,,151234941,1,HIV infection
15123496,151234961,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064231,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234961,OT,,,,,,,,,151234961,1,HIV infection
15123497,151234971,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064236,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234971,OT,,,,,,,,,151234971,1,HIV infection
15123498,151234981,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064201,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151234981,OT,,,,,,,,,151234981,1,HIV infection
15123499,151234991,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064234,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151234991,OT,,,,,,,,,151234991,1,HIV infection
15123501,151235011,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064229,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151235011,OT,,,,,,,,,151235011,1,HIV infection
15123503,151235031,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064232,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151235031,OT,,,,,,,,,151235031,1,HIV infection
15123505,151235051,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064246,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Neurotoxicity,151235051,OT,,,,,,,,,151235051,1,HIV infection
15123506,151235061,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064198,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235061,OT,,,,,,,,,151235061,1,HIV infection
15123507,151235071,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064199,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235071,OT,,,,,,,,,151235071,1,HIV infection
15123508,151235081,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064196,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235081,OT,,,,,,,,,151235081,1,HIV infection
15123509,151235091,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064235,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Metabolic disorder,151235091,OT,,,,,,,,,151235091,1,HIV infection
15123510,151235102,2,F,,20180625,20180709,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064249,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710,,OT,GB,IT,EFAVIRENZ.,Toxicity to various agents,151235102,OT,,,,,,,,,151235102,1,HIV infection
15123511,151235111,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064197,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235111,OT,,,,,,,,,151235111,1,HIV infection
15123512,151235121,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064200,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235121,OT,,,,,,,,,151235121,1,HIV infection
15123517,151235171,1,I,,20180625,20180709,20180709,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064202,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180709,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151235171,OT,,,,,,,,,151235171,1,HIV infection
15123524,151235242,2,F,,20180625,20180709,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064255,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710,,OT,GB,IT,EFAVIRENZ.,Toxicity to various agents,151235242,OT,,,,,,,,,151235242,1,HIV infection
15123525,151235252,2,F,,20180625,20180709,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064253,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710,,OT,GB,IT,EFAVIRENZ.,Toxicity to various agents,151235252,OT,,,,,,,,,151235252,1,HIV infection
15123526,151235262,2,F,,20180625,20180709,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064254,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710,,OT,GB,IT,EFAVIRENZ.,Toxicity to various agents,151235262,OT,,,,,,,,,151235262,1,HIV infection
15123527,151235272,2,F,,20180625,20180709,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064256,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710,,OT,GB,IT,EFAVIRENZ.,Toxicity to various agents,151235272,OT,,,,,,,,,151235272,1,HIV infection
15123625,151236257,7,F,20180205,20180907,20180710,20180914,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20180914,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy;Product use issue,151236257,OT,,,151236257,3,20171006,20180205,,,151236257,1,HIV infection
15123626,151236266,6,F,20180112,20180907,20180710,20180914,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063878,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180914,,OT,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,151236266,OT,,,151236266,1,20171006,20180205,,,151236266,1,Product used for unknown indication
15123914,151239141,1,I,,20180625,20180710,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064193,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710,,OT,GB,IT,EFAVIRENZ.,Nephropathy toxic,151239141,OT,,,,,,,,,151239141,1,HIV infection
15124065,151240651,1,I,,20180625,20180710,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064218,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710,,OT,GB,IT,EFAVIRENZ.,Drug intolerance;Lipodystrophy acquired,151240651,OT,,,,,,,,,151240651,1,HIV infection
15124276,151242761,1,I,,20180628,20180710,20180710,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-061059,BRISTOL MYERS SQUIBB,,44,YR,,,Y,,,20180710,,CN,GB,GB,EFAVIRENZ.,Death,151242761,DE,,,,,,,,,151242761,1,HIV infection
15124395,151243951,1,I,,20180627,20180710,20180710,EXP,GB-MHRA-EYC 00181171,GB-LUPIN PHARMACEUTICALS INC.-2018-04870,LUPIN,,44,YR,,,Y,,,20180710,,CN,GB,GB,EFAVIRENZ.,Death,151243951,OT,,,,,,,,,151243951,1,HIV infection
15124577,151245771,1,I,,20180625,20180710,20180710,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-064219,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180710,,OT,GB,IT,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE;EFAVIRENZ.",Drug intolerance;Lipodystrophy acquired,151245771,OT,,,,,,,,,151245771,1,HIV infection
15126436,151264361,1,I,,20180628,20180710,20180710,EXP,,PT-MYLANLABS-2018M1049483,MYLAN,"LOUREIRO RV, COSTA MN, GERMANO I, CALINAS F. PSEUDORESISTANCE OF HEPATITIS B VIRUS TO TENOFOVIR WITH EMTRICITABINE. AIDS 2018?32(10):1387?1388.",52,YR,,M,Y,,,20180707,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug interaction;Therapeutic response decreased,151264361,OT,,,151264361,2,201206,,,,151264361,1,Hepatitis B
15127694,151276941,1,I,,20180508,20180710,20180710,EXP,,DE-MYLANLABS-2018M1031482,MYLAN,,25,YR,,F,Y,,,20180707,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,151276941,OT,,,,,,,,,151276941,1,Product used for unknown indication
15127888,151278881,1,I,201803,20180709,20180710,20180710,EXP,,US-GILEAD-2018-0349380,GILEAD,,50,YR,A,M,Y,,,20180710,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,151278881,OT,,,,,,,,,151278881,1,HIV infection
15131489,151314891,1,I,,20180629,20180711,20180711,EXP,,GB-MYLANLABS-2018M1048847,MYLAN,"WYNBERG E, WILLIAMS E, TUDOR?WILLIAMS G, LYALL H, LYALL C.. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?. CLIN DRUG INVESTIG.. 2018?38(3):231?8",,,C,,Y,,,20180708,,OT,GB,GB,EFAVIRENZ.,Stevens-Johnson syndrome,151314891,OT,,,,,,,,,151314891,1,Perinatal HIV infection
15133729,151337292,2,F,20180205,20180710,20180712,20180720,EXP,,GB-HETERO CORPORATE-HET2018GB00593,HETERO,,,,,F,Y,,,20180720,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Maternal exposure during pregnancy,151337292,OT,,,,,,,,,151337292,1,HIV infection
15135037,151350371,1,I,,20180627,20180712,20180712,EXP,,GB-AUROBINDO-AUR-APL-2018-034945,AUROBINDO,,44,YR,,,Y,,,20180712,,CN,GB,GB,EFAVIRENZ.,Death,151350371,DE,,,,,,,,,151350371,1,HIV infection
15139436,151394361,1,I,20121128,20130214,20180713,20180713,EXP,,BR-HETERO CORPORATE-2013HINSPO0158,HETERO,,0,DY,,F,Y,2.88,KG,20180713,,OT,BR,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,151394361,OT,,,151394361,3,20120521,20120803,,,151394361,1,Acquired immunodeficiency syndrome
15142503,151425031,1,I,,20180508,20180713,20180713,EXP,,DE-MYLANLABS-2018M1031564,MYLAN,,28,YR,,M,Y,,,20180713,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,151425031,OT,,,,,,,,,151425031,1,Product used for unknown indication
15144564,151445641,1,I,,20180508,20180713,20180713,EXP,,DE-MYLANLABS-2018M1031509,MYLAN,,43,YR,,F,Y,,,20180713,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,151445641,OT,,,,,,,,,151445641,1,Product used for unknown indication
15144880,151448801,1,I,200812,20180704,20180713,20180713,EXP,,JP-MYLANLABS-2018M1051655,MYLAN,,7,DEC,,M,Y,,,20180713,,OT,JP,JP,EFAVIRENZ.,Basedow's disease;Endocrine ophthalmopathy;Epistaxis;Immune reconstitution inflammatory syndrome;Immune thrombocytopenic purpura,151448801,OT,,,151448801,1,200606,,,,151448801,1,HIV infection
15150763,151507631,1,I,,20180705,20180716,20180716,EXP,,ES-MYLANLABS-2018M1050661,MYLAN,,46,YR,,,Y,,,20180716,,MD,ES,ES,EFAVIRENZ.,Drug withdrawal maintenance therapy;Nervous system disorder;Neurodermatitis;Treatment noncompliance;Weight decreased,151507631,OT,,,,,,,,,151507631,1,HIV infection
15151308,151513081,1,I,,20150610,20180716,20180716,PER,,US-009507513-1506USA006414,MERCK,,25,YR,,F,Y,,,20180716,,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;No adverse event,,,,,,,,,,,,,
15152012,151520122,2,F,,20180921,20180717,20180927,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063262,BRISTOL MYERS SQUIBB,,,,N,F,Y,,,20180927,,CN,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,151520122,CA,,,151520122,1,20110301,20180601,,,151520122,1,Product used for unknown indication
15155265,151552653,3,F,,20180704,20180717,20180717,EXP,,PHHY2018IE047182,ALCON,,37,YR,,F,Y,,,20180717,,OT,IE,IE,EFAVIRENZ.,Cushingoid;Drug ineffective for unapproved indication;Leukopenia;Off label use;Product use in unapproved indication;Skin atrophy,151552653,OT,,,,,,,,,151552653,1,Cutaneous sarcoidosis
15157399,151573991,1,I,,20180713,20180718,20180718,EXP,GB-MHRA-EYC 00181171,GB-TEVA-2018-GB-926820,TEVA,,44,YR,,,Y,,,20180718,,CN,GB,GB,EFAVIRENZ.,Death,151573991,DE,,,,,,,,,151573991,1,HIV infection
15158092,151580921,1,I,,20180703,20180718,20180718,EXP,,PT-AUROBINDO-AUR-APL-2018-036024,AUROBINDO,,27,YR,,F,Y,,,20180718,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,151580921,OT,,,151580921,2,2007,,,,151580921,1,HIV infection
15158165,151581652,2,F,20171006,20180715,20180718,20180730,EXP,,GB-AUROBINDO-AUR-APL-2018-036078,AUROBINDO,,43,YR,,F,Y,,,20180730,,CN,GB,GB,Efavirenz Film?coated Tablet,Abortion spontaneous;Maternal exposure during pregnancy,151581652,OT,,,,,,,,,151581652,1,HIV infection
15158285,151582851,1,I,2015,20180706,20180718,20180718,EXP,,RO-MYLANLABS-2018M1051210,MYLAN,"CAMBREA SC, PASCU C, RUGINA S.. HEMIBALLISMUS IN A PATIENT WITH ACQUIRED IMMUNODEFICIENCY SYNDROME AND TOXOPLASMA INFECTION.. ROMANIAN JOURNAL OF INFECTIOUS DISEASES. 2017?20(1):20?5, 47?52",28,YR,,F,Y,,,20180713,,OT,RO,RO,EFAVIRENZ.,Ballismus;Brain oedema;Central nervous system lesion;Cerebral toxoplasmosis;Intracranial mass;Loss of consciousness;Motor dysfunction;Product use issue,151582851,HO,,,151582851,4,2015,,,,151582851,1,HIV infection
15158366,151583662,2,F,20150224,20180711,20180718,20180726,EXP,,FR-CONCORDIA PHARMACEUTICALS INC.-E2B_00014087,CONCORDIA,,,,,M,Y,,,20180726,,CN,US,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Muscle atrophy;Small for dates baby,151583662,CA,,,151583662,12,20150608,20150608,,,151583662,1,Product used for unknown indication
15158807,151588071,1,I,20150608,20180713,20180718,20180718,EXP,,FR-BAUSCH-BL-2018-019463,BAUSCH AND LOMB,,0,DY,,M,Y,,,20180718,,CN,US,FR,SUSTIVA,Foetal exposure during pregnancy;Low birth weight baby;Muscle atrophy;Small for dates baby,151588071,CA,,,151588071,5,20150608,20150608,,,151588071,1,Product used for unknown indication
15164880,151648801,1,I,20150608,20180713,20180719,20180719,EXP,,FR-BAUSCH-BL-2018-019465,BAUSCH AND LOMB,,37,YR,,F,Y,,,20180719,,CN,US,FR,SUSTIVA,Exposure during pregnancy;Foetal growth restriction;Live birth,151648801,OT,,,151648801,2,20150608,20150608,,,151648801,1,Product used for unknown indication
15169075,151690751,1,I,,20180705,20180720,20180720,EXP,,GB-AUROBINDO-AUR-APL-2018-036152,AUROBINDO,,,,N,F,Y,,,20180720,,MD,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,151690751,CA,,,151690751,1,201103,201806,,,151690751,1,HIV infection
15169200,151692001,1,I,,20180710,20180720,20180720,EXP,,PT-GILEAD-2018-0349806,GILEAD,SOEIRO C? TAVARES AP? CASTRO RS. HEPATITIS B REACTIVATION AFTER HCV TREATMENT WITH SOFOSBUVIR/LEDIPASVIR IN A HIV?COINFECTED PATIENT WITH PREVIOUS POSITIVE ANTI?HBS ANTIBODY: A CASE REPORT AND A REVIEW OF LITERATURE. HIV + AIDS REVIEW. 2018?17(2):146?151,54,YR,A,M,Y,,,20180720,,MD,PT,PT,EFAVIRENZ.,Hepatitis B reactivation,151692001,OT,,,,,,,,,151692001,1,Chronic hepatitis C
15169266,151692664,4,F,20160209,20180924,20180720,20180927,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-068119,BRISTOL MYERS SQUIBB,,31,YR,,M,Y,67.3,KG,20180927,,OT,MW,MW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Blood creatinine increased;Malaria,151692664,LT,,,151692664,1,20150527,20160208,,,151692664,1,Antiretroviral therapy
15170786,151707862,2,F,20180615,20180718,20180720,20180724,EXP,,LS-JNJFOC-20180714944,JANSSEN,,47,YR,A,F,Y,61,KG,20180724,,MD,LS,LS,EFAVIRENZ.,Haemoglobin decreased;Muscle spasms;Renal failure;Vomiting,151707862,HO,,,151707862,1,20180612,20180701,,,151707862,1,Tuberculosis
15171605,151716051,1,I,,20180710,20180720,20180720,EXP,,GB-MYLANLABS-2018M1052844,MYLAN,"WYNBERG E, WILLIAMS E, TUDOR?WILLIAMS G, LYALL H, FOSTER C.. DISCONTINUATION OF EFAVIRENZ IN PAEDIATRIC PATIENTS: WHY DO CHILDREN SWITCH?.. CLINICAL DRUG INVESTIGATION.. 2018?38:231?8",,,,,Y,,,20180716,,OT,GB,GB,EFAVIRENZ.,Learning disorder;Psychotic symptom,151716051,OT,,,,,,,,,151716051,1,Perinatal HIV infection
15173151,151731518,8,F,2014,20180921,20180720,20180924,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-067368,BRISTOL MYERS SQUIBB,,39,YR,,M,Y,,,20180924,,OT,ES,ES,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Acute coronary syndrome;Drug interaction;Vascular stent thrombosis,151731518,HO,,,,,,,,,151731518,1,Antiplatelet therapy
15177922,151779221,1,I,,20180517,20180720,20180720,EXP,,PHHY2018GB006067,NOVARTIS,,,,,F,Y,,,20180721,,CN,GB,GB,EFAVIRENZ.,Asthenia;Blood oestrogen decreased;Drug dependence;Drug ineffective;Drug interaction;Incorrect dose administered;Product adhesion issue;Product prescribing issue,151779221,OT,,,,,,,,,151779221,1,Hormone replacement therapy
15178674,151786742,2,F,20100716,20180614,20180722,20180801,EXP,,GB-009507513-1106GBR00040B1,MERCK,,0,DY,,F,Y,1.37,KG,20180801,,CN,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Low birth weight baby;Premature baby;Small for dates baby,151786742,OT,,,,,,,,,,,
15180335,151803351,1,I,20171006,20180716,20180723,20180723,EXP,,GB-BAUSCH-BL-2018-019695,BAUSCH AND LOMB,,43,YR,,F,Y,,,20180723,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,151803351,OT,,,,,,,,,151803351,1,Product used for unknown indication
15180832,151808322,2,F,20180112,20180803,20180723,20180810,EXP,,GB-AUROBINDO-AUR-APL-2018-036898,AUROBINDO,,,,,M,Y,,,20180810,,CN,GB,GB,Efavirenz Film?coated Tablet,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,151808322,CA,,,,,,,,,151808322,1,Product used for unknown indication
15183751,151837511,1,I,,20180711,20180723,20180723,EXP,GB-MHRA-EYC 00171779,GB-MYLANLABS-2018M1053986,MYLAN,,47,YR,,F,Y,109,KG,20180716,,PH,GB,GB,EFAVIRENZ.,Acute hepatic failure;Death;Hepatic necrosis;Jaundice,151837511,DE,,,151837511,1,20161004,20171215,,,151837511,1,HIV infection
15184038,151840381,1,I,20180305,20180711,20180723,20180723,EXP,ES-AEMPS-345940,ES-MYLANLABS-2018M1053697,MYLAN,,48,YR,,M,Y,,,20180723,,MD,ES,ES,EFAVIRENZ SANDOZ,Abnormal dreams;Feeling hot;Insomnia,151840381,OT,,,151840381,1,20180302,20180322,,,151840381,1,HIV infection
15184040,151840401,1,I,20180625,,20180625,20180625,DIR,,,FDA-CTU,,50,YR,,M,N,,,20180625,N,PH,US,US,EFAVIRENZ TAB 600MG,Lipids increased,,,151840401,HP,151840401,1,20170625,20180625,,,,,
15188355,151883551,1,I,,20180712,20180724,20180724,EXP,,IN-CIPLA LTD.-2018IN20050,CIPLA,,,,,,Y,,,20180724,,OT,IN,IN,EFAVIRENZ.,Central nervous system immune reconstitution inflammatory response;Death;Meningitis cryptococcal,151883551,HO,,,,,,,,,151883551,1,HIV infection
15190280,151902801,1,I,,20180711,20180724,20180724,EXP,,GB-MYLANLABS-2018M1053758,MYLAN,,46,YR,,M,Y,,,20180724,,MD,GB,GB,EFAVIRENZ.,Renal failure,151902801,OT,,,,,,,,,151902801,1,HIV infection
15190757,151907575,5,F,20151104,20180822,20180724,20180831,EXP,,MW-GILEAD-2018-0351189,GILEAD,,36,YR,A,M,Y,70.6,KG,20180831,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alanine aminotransferase increased;Aspartate aminotransferase increased;Blood alkaline phosphatase increased;Blood bilirubin increased;Carbon dioxide abnormal;Platelet count decreased;Transaminases increased,151907575,OT,,,151907575,1,20150305,20160323,,,151907575,1,Antiretroviral therapy
15190772,151907721,1,I,20160209,20180717,20180724,20180724,EXP,,MW-GILEAD-2018-0351226,GILEAD,,34,YR,A,M,Y,67.3,KG,20180724,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood creatinine increased,151907721,LT,,,151907721,1,20150527,20150916,,,151907721,1,Antiretroviral therapy
15192933,151929331,1,I,20150608,20180716,20180725,20180725,EXP,FR-EMA-DD-20171219-SHAEVHP-101717,FR-ACCORD-069879,ACCORD,,0,DY,,M,Y,2.64,KG,20180725,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Small for dates baby,151929331,OT,,,151929331,4,20150608,20150608,,,151929331,1,Product used for unknown indication
15193162,151931622,2,F,,20180827,20180725,20180903,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-068468,BRISTOL MYERS SQUIBB,,64,YR,,M,Y,,,20180903,,OT,US,US,EFAVIRENZ.,Acute myocardial infarction;Drug interaction;Pulmonary embolism,151931622,OT,,,,,,,,,151931622,1,Cerebrovascular accident prophylaxis
15195615,151956151,1,I,20150608,20180112,20180725,20180725,EXP,,FR-AUROBINDO-AUR-APL-2018-002734,AUROBINDO,,37,YR,,F,Y,,,20180725,,CN,US,FR,SUSTIVA,Foetal growth restriction;Live birth;Maternal exposure during pregnancy,151956151,OT,,,151956151,7,20150608,20150608,,,151956151,1,HIV infection
15200322,152003221,1,I,,20100709,20180726,20180726,PER,,US-009507513-1007USA01170,MERCK,,18,YR,,F,Y,,,20180726,,CN,US,US,efavirenz (+) emtricitabine (+) tenofovir disoproxil fumarate,Maternal exposure during pregnancy;No adverse event,,,,,,,,,,,,,
15203220,152032201,1,I,,20110607,20180726,20180726,EXP,,GB-009507513-1106GBR00040,MERCK,,31,YR,,F,Y,,,20180726,,CN,GB,GB,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,152032201,OT,,,,,,,,,,,
15204215,152042151,1,I,20171006,20180716,20180726,20180726,EXP,,GB-BAUSCH-BL-2018-019701,BAUSCH AND LOMB,,,,,M,Y,,,20180726,,OT,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,152042151,CA,,,152042151,2,20171006,20180205,,,152042151,1,Product used for unknown indication
15205851,152058511,1,I,,20180723,20180727,20180727,EXP,,US-STRIDES ARCOLAB LIMITED-2018SP006194,STRIDES,"APONTE J, SALONIA J, STOEVER J, SHUJAAT A.. WHEN NOT TO CHOOSE APIXABAN: A CASE OF APIXABAN FAILURE.. AM?J?RESPIR?CRIT?CARE?MED. 2018?197",,,,,Y,,,20180727,,OT,US,US,EFAVIRENZ.,Drug interaction;Pulmonary embolism;Thrombosis,152058511,OT,,,,,,,,,152058511,1,HIV infection
15207054,152070541,1,I,20051226,20100629,20180727,20180727,EXP,,US-VIIV HEALTHCARE LIMITED-US2010000242,VIIV,,0,DY,,,Y,,,20180727,,OT,US,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,152070541,CA,,,,,,,,,152070541,1,HIV infection
15207059,152070591,1,I,20051226,20100629,20180727,20180727,EXP,,US-GLAXOSMITHKLINE-US2010000242,GLAXOSMITHKLINE,,0,DY,,,Y,,,20180727,,OT,US,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,152070591,CA,,,,,,,,,152070591,1,HIV infection
15209935,152099351,1,I,,20180717,20180727,20180727,EXP,,PT-MYLANLABS-2018M1056119,MYLAN,"SOEIRO C, TAVARES AP, E CASTRO RS. HEPATITIS B REACTIVATION AFTER HCV TREATMENT WITH SOFOSBUVIR/LEDIPASVIR IN A HIV?COINFECTED PATIENT WITH PREVIOUS POSITIVE ANTI?HBS ANTIBODY: A CASE REPORT AND A REVIEW OF LITERATURE. HIV?AIDS?REV 2018?17(2):146?151.",54,YR,,M,Y,,,20180726,,MD,PT,PT,EFAVIRENZ.,Hepatitis B reactivation;Neuropsychiatric symptoms,152099351,OT,,,152099351,1,2014,,,,152099351,1,HIV infection
15214568,152145683,3,F,20050813,20180924,20180730,20180924,EXP,,FR-VIIV HEALTHCARE LIMITED-B0561595A,VIIV,,25,YR,,F,Y,,,20180924,,MD,FR,FR,EFAVIRENZ.,Abortion induced;Exposure during pregnancy;Insomnia;Vertigo,152145683,OT,,,152145683,1,20050908,20050908,,,152145683,1,HIV infection
15214571,152145711,1,I,,20090219,20180730,20180730,EXP,,FR-VIIV HEALTHCARE LIMITED-B0561595B,VIIV,,,,N,,Y,,,20180730,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,152145711,OT,,,152145711,1,20050908,20050908,,,152145711,1,HIV infection
15214767,152147672,2,F,,20180719,20180730,20180802,EXP,,ES-JNJFOC-20180716511,JOHNSON AND JOHNSON,"JIMENEZ GUERRERO L, NUNEZ NUNEZ M, CASTANEDA MACIAS I, SANDOVAL FERNANDEZ DEL CASTILLO S. POTENTIAL INTERACTIONS IN A COHORT OF ELDERLY HIV?POSITIVE PATIENTS. FARMACIA HOSPITALARIA 2017?42 (4):163?167.",,,A,,Y,,,20180802,,OT,ES,ES,EFAVIRENZ.,Drug interaction;Drug level increased;Hepatotoxicity;Nephropathy toxic,152147672,OT,,,,,,,,,152147672,2,Product used for unknown indication
15215295,152152951,1,I,20170904,20180717,20180730,20180730,EXP,,ET-SA-2018SA196264,SANOFI AVENTIS,,,,A,F,Y,,,20180730,,OT,ET,ET,EFAVIRENZ.,Seizure,152152951,OT,,,,,,,,,152152951,1,Antibiotic prophylaxis
15217110,152171101,1,I,20141011,20180726,20180730,20180730,EXP,,ZA-GILEAD-2018-0352419,GILEAD,,28,YR,A,F,Y,,,20180730,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,152171101,OT,,,152171101,1,20140604,,,,152171101,1,HIV infection
15220456,152204561,1,I,,20180719,20180731,20180731,EXP,,JP-MYLANLABS-2018M1057761,MYLAN,"KOIZUMI Y, IMADOME K?I, OTA Y, MINAMIGUCHI H, KODAMA Y, WATANABE D, ET AL. DUAL THREAT OF EPSTEIN?BARR VIRUS: AN AUTOPSY CASE REPORT OF HIV?POSITIVE PLASMABLASTIC LYMPHOMA COMPLICATING EBV?ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS. J?CLIN?IMMUNOL 2018?38(4):478?483.. 2018?38(4):478?483",53,YR,,M,Y,,,20180730,,OT,JP,JP,EFAVIRENZ.,Bone marrow failure;Cystitis;Embolism;Epstein-Barr virus infection;Escherichia bacteraemia;Haemorrhage;Histiocytosis haematophagic;Multiple organ dysfunction syndrome;Septic shock;Systemic mycosis;Urosepsis,152204561,OT,,,,,,,,,152204561,1,Immunosuppressant drug therapy
15222669,152226691,1,I,,20180718,20180731,20180731,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-071122,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20180731,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy;Product use issue,152226691,OT,,,,,,,,,152226691,1,Product used for unknown indication
15222670,152226701,1,I,,20180718,20180731,20180731,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-067824,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20180731,,OT,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,152226701,OT,,,,,,,,,152226701,1,Product used for unknown indication
15223167,152231671,1,I,,20180720,20180731,20180731,EXP,,PHHY2018JP053668,SANDOZ,"KOIZUMI Y, IMADOME K, OTA Y, MINAMIGUCHI H, KODAMA Y, WATANABE D ET AL.. DUAL THREAT OF EPSTEIN?BARR VIRUS: AN AUTOPSY CASE REPORT OF HIV?POSITIVE PLASMABLASTIC LYMPHOMA COMPLICATING EBV?ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS. JOURNAL OF CLINICAL IMMUNOLOGY. 2018?38(4):478?83",53,YR,,M,Y,,,20180731,,OT,JP,JP,EFAVIRENZ.,Bone marrow failure;Cystitis;Escherichia infection;Haemorrhage;Histiocytosis haematophagic;Multiple organ dysfunction syndrome;Septic shock;Systemic mycosis;Therapeutic response decreased,152231671,DE,,,,,,,,,152231671,1,Plasmablastic lymphoma
15227421,152274211,1,I,,20180724,20180801,20180801,EXP,,ES-ASTRAZENECA-2018SE94890,ASTRAZENECA,,39,YR,,M,Y,,,20180801,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Drug interaction;Vascular stent thrombosis,152274211,HO,,,,,,,,,152274211,1,Antiplatelet therapy
15228449,152284491,1,I,,20180718,20180801,20180801,EXP,,US-MYLANLABS-2018M1056860,MYLAN,"APONTE J, SALONIA J, STOEVER J, SHUJAAT A. WHEN NOT TO CHOOSE APIXABAN: A CASE OF APIXABAN FAILURE. AM?J?RESPIR?CRIT?CARE?MED 2018?197: ABSTR. A3451.",64,YR,,M,Y,,,20180801,,OT,US,US,EFAVIRENZ.,Drug interaction;Pulmonary embolism,152284491,OT,,,,,,,,,152284491,1,HIV infection
15229518,152295181,1,I,,20180606,20180802,20180802,PER,,US-STRIDES ARCOLAB LIMITED-2018SP004642,STRIDES,SHARMA AV. DRUG?DRUG INTERACTION LEADING TO FANCONI^S SYNDROME IN A GERIATRIC PATIENT. J?AM?GERIATR?SOC. 2018?66 (SUPPL. 2):S17,,,,,Y,,,20180802,,OT,US,US,EFAVIRENZ.,Chest pain;Drug interaction;Fanconi syndrome acquired;Nausea;Vomiting,152295181,OT,,,,,,,,,152295181,1,HIV infection
15229519,152295191,1,I,,20180723,20180802,20180802,PER,,US-STRIDES ARCOLAB LIMITED-2018SP006173,STRIDES,"HASSAN S?A, SIDDIQUI A, BURKS J, KAWJI M.. A RARE CAUSE OF GRAVES DISEASE IN HIV INFECTION. ENDOCR? PRACT. 2018?24 (SUPPL.1):264?265",,,,,Y,,,20180802,,MD,US,US,EFAVIRENZ.,Anxiety;Basedow's disease;Endocrine ophthalmopathy;Exophthalmos;Goitre;Hyperthyroidism;Immune reconstitution inflammatory syndrome;Insomnia;Lid lag;Palpitations;Temperature intolerance;Tremor;Weight decreased,152295191,OT,,,,,,,,,152295191,1,HIV infection
15229875,152298751,1,I,,20180327,20180802,20180802,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2018US-169287,RANBAXY,"BAUMRIN E, MOSAM A, DLOVA NC. GIANT ANNULAR LICHENOID DRUG ERUPTION CAUSED BY EFAVIRENZ THERAPY. JAAD CASE REP. 2018?APR? 4(3):256?258",40,YR,,M,Y,,,20180802,,MD,US,US,EFAVIRENZ.,Lichenoid keratosis,152298751,OT,,,,,,,,,152298751,1,Antiretroviral therapy
15230085,152300851,1,I,,20180725,20180802,20180802,EXP,,IN-CIPLA LTD.-2018IN20418,CIPLA,"SEHGAL VN, VERMA P, SHARMA S. HIV/AIDS KAPOSI SARCOMA: THE INDIAN PERSPECTIVE. SKINMED. 2013?11 (6):375 TO 377",,,,,Y,,,20180802,,OT,IN,IN,EFAVIRENZ.,Drug ineffective;Pulmonary tuberculosis,152300851,OT,,,,,,,,,152300851,1,Antiretroviral therapy
15232816,152328161,1,I,20150326,20180730,20180802,20180802,EXP,,ZA-GILEAD-2018-0352807,GILEAD,,39,YR,A,F,Y,,,20180802,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,152328161,OT,,,152328161,1,20140212,,,,152328161,1,Product used for unknown indication
15234354,152343541,1,I,,20180723,20180803,20180803,EXP,,US-HETERO CORPORATE-HET2018US00719,HETERO,"APONTE J, SALONIA J, STOEVER J, SHUJAAT A. WHEN NOT TO CHOOSE APIXABAN: A CASE OF APIXABAN FAILURE. AM?J?RESPIR?CRIT?CARE?MED. 2018?197:A3451",64,YR,,M,Y,,,20180803,,OT,US,US,EFAVIRENZ.,Drug interaction;Pulmonary embolism,152343541,OT,,,,,,,,,152343541,1,HIV infection
15235019,152350192,2,F,2006,20180807,20180803,20180809,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-002637",BOEHRINGER INGELHEIM,,,,N,F,Y,1.19,KG,20180809,,OT,FR,FR,SUSTIVA,Brain herniation;Foetal exposure during pregnancy;Foetal malformation;Spina bifida,152350192,DE,,,152350192,1,20050704,20060216,,,152350192,1,HIV infection
15236145,152361451,1,I,20180706,,20180709,20180709,DIR,,,FDA-CTU,,20,YR,,M,N,,,20180709,N,OT,US,US,EFAVIRENZ.;SUSTIVA,Pneumonia,152361451,HO,152361451,HP,152361451,1,20160420,,,,152361451,1,HIV infection
15238000,152380001,1,I,,20180720,20180803,20180803,EXP,,FR-MYLANLABS-2018M1057026,MYLAN,,,,,,Y,,,20180727,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myositis,152380001,OT,,,,,,,,,152380001,1,HIV infection
15238115,152381154,4,F,2014,20180831,20180803,20180914,EXP,,ES-AUROBINDO-AUR-APL-2018-039058,AUROBINDO,,39,YR,,M,Y,,,20180914,,OT,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,152381154,OT,,,152381154,1,2012,,,,152381154,1,HIV infection
15238591,152385911,1,I,,20180727,20180803,20180803,EXP,,GB-GILEAD-2018-0353186,GILEAD,,41,YR,A,M,Y,,,20180803,,OT,GB,GB,EFAVIRENZ.,Autoimmune hepatitis,152385911,OT,,,,,,,,,152385911,1,Product used for unknown indication
15239133,152391332,2,F,,20180810,20180803,20180817,EXP,,GB-GILEAD-2018-0353190,GILEAD,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS. SCAND J GASTROENTEROL. 2016?51(7):814?8",42,YR,A,F,Y,,,20180817,,OT,ZA,ZA,EFAVIRENZ.,Autoimmune hepatitis,152391332,OT,,,,,,,,,152391332,1,HIV infection
15239979,152399792,2,F,,20180810,20180803,20180817,EXP,,ZA-GILEAD-2018-0353191,GILEAD,"MURUNGA E, ANDERSSON M, RENSBURG CV.. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND J GASTROENTEROL.. 2016?51(7):814?8",45,YR,A,F,Y,,,20180817,,MD,ZA,ZA,EFAVIRENZ.,Autoimmune hepatitis,152399792,OT,,,,,,,,,152399792,1,HIV infection
15239997,152399972,2,F,,20180810,20180803,20180817,EXP,,ZA-GILEAD-2018-0353194,GILEAD,"MURUNGA E, ANDERSSON M, RENSBURG CV. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND J GASTROENTEROL. 2016?51(7):814?8",39,YR,A,F,Y,,,20180817,,OT,ZA,ZA,EFAVIRENZ.,Autoimmune hepatitis,152399972,OT,,,,,,,,,152399972,1,HIV infection
15240014,152400141,1,I,,20180727,20180803,20180803,EXP,,US-GILEAD-2018-0353206,GILEAD,,45,YR,A,F,Y,,,20180803,,MD,US,US,EFAVIRENZ.,Autoimmune hepatitis,152400141,OT,,,152400141,1,200405,200502,,,152400141,1,HIV infection
15240105,152401052,2,F,,20180810,20180803,20180817,EXP,,GB-GILEAD-2018-0353197,GILEAD,"MURUNGA E, ANDERSSON M, RENSBURG CV.. AUTOIMMUNE HEPATITIS: A MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV INFECTED PATIENTS?. SCAND J GASTROENTEROL.. 2016?51(7):814?8",43,YR,A,F,Y,,,20180817,,MD,GB,GB,EFAVIRENZ.,Autoimmune hepatitis,152401052,OT,,,,,,,,,152401052,1,HIV infection
15242740,152427401,1,I,,20180723,20180806,20180806,EXP,,US-AUROBINDO-AUR-APL-2018-039256,AUROBINDO,SWINDELLS.. EFAVIRENZ IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: CASE REPORT. REACTIONS WEEKLY. 2018?1711:P113,54,YR,,F,Y,,,20180806,,OT,US,US,EFAVIRENZ.,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Lung infiltration;Pyrexia;Weight decreased,152427401,HO,,,,,,,,,152427401,1,HIV infection
15243637,152436371,1,I,20060216,20180803,20180806,20180806,EXP,,FR-ABBVIE-18S-056-2442144-00,ABBVIE,,25,YR,,F,Y,,,20180806,,MD,FR,FR,SUSTIVA,Abortion induced;Exposure during pregnancy,152436371,CA,,,152436371,1,20050908,20050908,,,152436371,1,HIV infection
15244728,152447281,1,I,20180712,,20180712,20180712,DIR,,,FDA-CTU,,68,YR,,M,N,,,20180712,N,PH,US,US,SUSTIVA,Renal disorder;Renal injury;Rheumatoid arthritis,,,152447281,HP,152447281,1,,,5,YR,,,
15245128,152451281,1,I,20180209,20180731,20180806,20180806,EXP,,LS-GLAXOSMITHKLINE-LS2018GSK140125,GLAXOSMITHKLINE,,26,YR,,M,Y,45,KG,20180806,,CN,LS,LS,EFAVIRENZ.,Alanine aminotransferase increased;Altered state of consciousness;Aspartate aminotransferase increased;Dehydration;Dizziness;Feeling drunk;Gamma-glutamyltransferase increased;Hyperlactacidaemia;Hypokalaemia;Hypophagia;Hypotension;Hypothyroidism;Intestinal ischaemia;Metabolic acidosis;Oral herpes;Pneumocystis jirovecii pneumonia;Pulmonary embolism;Syncope;Tremor;Vomiting,152451281,OT,,,152451281,1,20180216,20180715,,,152451281,1,HIV infection
15245584,152455841,1,I,,20180724,20180806,20180806,EXP,,PHHY2018IT059299,SANDOZ,,,,,,Y,,,20180806,,OT,COUNTRY NOT SPECIFIED,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,152455841,OT,,,,,,,,,152455841,1,HIV infection
15246169,152461691,1,I,20180209,20180731,20180806,20180806,EXP,,LS-VIIV HEALTHCARE LIMITED-LS2018GSK140125,VIIV,,26,YR,,M,Y,45,KG,20180806,,CN,LS,LS,EFAVIRENZ.,Alanine aminotransferase increased;Altered state of consciousness;Aspartate aminotransferase increased;Dehydration;Dizziness;Feeling drunk;Gamma-glutamyltransferase increased;Hyperlactacidaemia;Hypokalaemia;Hypophagia;Hypotension;Hypothyroidism;Intestinal ischaemia;Metabolic acidosis;Oral herpes;Pneumocystis jirovecii pneumonia;Pulmonary embolism;Syncope;Tremor;Vomiting,152461691,OT,,,152461691,1,20180216,20180715,,,152461691,1,HIV infection
15247398,152473981,1,I,,20180730,20180807,20180807,EXP,,JP-TEVA-2018-JP-938357,TEVA,"KOIZUMI Y, IMADOME K?I, OTA Y, MINAMIGUCHI H, KODAMA Y, WATANABE D, ET AL. DUAL THREAT OF EPSTEIN?BARR VIRUS: AN AUTOPSY CASE REPORT OF HIV?POSITIVE PLASMABLASTIC LYMPHOMA COMPLICATING EBV?ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS. J?CLIN?IMMUNOL 2018?38(4):478?483.",53,YR,,M,Y,,,20180807,,OT,JP,JP,EFAVIRENZ.,Bone marrow failure;Cystitis;Embolism;Epstein-Barr virus infection;Escherichia bacteraemia;Haemorrhage;Histiocytosis haematophagic;Multiple organ dysfunction syndrome;Systemic mycosis;Urosepsis,152473981,OT,,,,,,,,,152473981,1,Immunosuppressant drug therapy
15249825,152498251,1,I,,20180725,20180807,20180807,EXP,,"MZ-LANNETT COMPANY, INC.-MZ-2018LAN000892",LANNETT,"ANTUNES M, SCHIAVONE M, PIZZOL D, DI GENNARO F, LUDOVICO R, DE PALMA A. BILATERAL MASTECTOMY AS RADICAL TREATMENT OF GYNECOMASTIA SECONDARY TO ANTIRETROVIRAL THERAPY IN A LOW?INCOME SETTING: A CASE REPORT. DRUG?SAF?CASE?REP. 2018?5(1):21",46,YR,,M,Y,,,20180807,,OT,MZ,MZ,EFAVIRENZ.,Gynaecomastia,152498251,HO,,,,,,,,,152498251,1,HIV infection
15249829,152498293,3,F,20060216,20180926,20180807,20180928,EXP,,FR-ABBVIE-18S-056-2444229-00,ABBVIE,,25,YR,,F,Y,,,20180928,,MD,FR,FR,EFAVIRENZ.,Abortion induced;Exposure during pregnancy;Insomnia;Vertigo,152498293,OT,,,152498293,1,20050908,20050908,,,152498293,1,HIV infection
15249841,152498412,2,F,,20180803,20180807,20180810,EXP,,FR-ABBVIE-18S-056-2442056-00,ABBVIE,,,,,F,Y,,,20180810,,MD,FR,FR,SUSTIVA,Arnold-Chiari malformation;Foetal exposure during pregnancy,152498412,OT,,,,,,,,,152498412,1,Maternal exposure timing unspecified
15249898,152498981,1,I,,20171009,20180807,20180807,EXP,,GB-GILEAD-2018-0353613,GILEAD,,,,A,,Y,,,20180807,,MD,GB,GB,SUSTIVA,Hepatitis B,152498981,OT,,,,,,,,,152498981,1,HIV infection
15250314,152503141,1,I,,20180725,20180807,20180807,EXP,,ES-MYLANLABS-2018M1059149,MYLAN,"BRAVO I, ALVAREZ H, MARINO A, CLOTET B, MOLTO J. RECURRENT CORONARY DISEASE IN HIV?INFECTED PATIENTS: ROLE OF DRUG?DRUG INTERACTIONS. BR?J?CLIN?PHARMACOL 2018?84(7):1617?1619.",39,YR,,M,Y,,,20180807,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Drug interaction;Vascular stent thrombosis,152503141,HO,,,,,,,,,152503141,1,HIV infection
15250406,152504062,2,F,,20180808,20180807,20180808,EXP,,FR-ABBVIE-18S-056-2444204-00,ABBVIE,,,,,,Y,,,20180808,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,152504062,OT,,,,,,,,,152504062,1,Maternal exposure timing unspecified
15253366,152533661,1,I,,20180730,20180808,20180808,EXP,,US-TEVA-2018-US-937952,TEVA,"HASSAN S?A, SIDDIQUI A, BURKS J, KAWJI M. A RARE CAUSE OF GRAVES DISEASE IN HIV INFECTION. ENDOCR?PRACT 2018?24 (SUPPL. 1):264?265 ABSTR. #1086.",5,DEC,,M,Y,,,20180808,,MD,US,US,EFAVIRENZ.,Basedow's disease;Endocrine ophthalmopathy;Immune reconstitution inflammatory syndrome,152533661,OT,,,,,,,,,152533661,1,HIV infection
15255990,152559902,2,F,201802,20180730,20180808,20180808,EXP,,PHHY2018LS063611,SANDOZ,,26,YR,,M,Y,45,KG,20180808,,CN,LS,LS,EFAVIRENZ.,Alanine aminotransferase increased;Altered state of consciousness;Aspartate aminotransferase increased;Dehydration;Dizziness;Feeling drunk;Gamma-glutamyltransferase increased;Gastroenteritis;Hyperlactacidaemia;Hypokalaemia;Hypophagia;Hypotension;Hypothyroidism;Intestinal ischaemia;Metabolic acidosis;Oral herpes;Pneumocystis jirovecii pneumonia;Pulmonary embolism;Syncope;Tachycardia;Tremor;Vomiting,152559902,OT,,,152559902,1,20180322,20180712,,,152559902,1,Tuberculosis
15258044,152580441,1,I,,20180730,20180809,20180809,EXP,,ES-HETERO CORPORATE-HET2018ES00749,HETERO,"BRAVO I, ALVAREZ H, MARINO A, CLOTET B, MOLTO J. RECURRENT CORONARY DISEASE IN HIV?INFECTED PATIENTS: ROLE OF DRUG?DRUG INTERACTIONS. BR?J?CLIN?PHARMACOL. 2018?84(7):1617?1619",39,YR,,M,Y,,,20180809,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Drug interaction;Myocardial infarction;Vascular stent thrombosis,152580441,OT,,,,,,,,,152580441,1,HIV infection
15258048,152580481,1,I,,20180730,20180809,20180809,EXP,,US-AUROBINDO-AUR-APL-2018-040451,AUROBINDO,,64,YR,,M,Y,,,20180809,,OT,US,US,EFAVIRENZ.,Atrial fibrillation;Deep vein thrombosis;Dyspnoea;Pulmonary embolism,152580481,OT,,,,,,,,,152580481,1,HIV infection
15265709,152657091,1,I,20150509,20180801,20180810,20180810,EXP,,ZA-GILEAD-2018-0353888,GILEAD,,34,YR,A,F,Y,,,20180810,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,152657091,OT,,,152657091,1,20140226,,,,152657091,1,HIV infection
15266069,152660691,1,I,,20180801,20180810,20180810,EXP,,BW-GILEAD-2018-0353848,GILEAD,"ZASH R, HOLMES L, MAKHEMA J, DISEKO M, JACOBSON D, MAYONDI G, MMALANE M, MOFENSON L, GAOLATHE T, PETLO C, ESSEX M, LOCKMAN S, SHAPIRO R. SURVEILLANCE FOR NEURAL TUBE DEFECTS FOLLOWING ANTIRETROVIRAL EXPOSURE FROM CONCEPTION. AIDS 2018 CONFERENCE. 2018?UNK:1?25",,,I,,Y,,,20180810,,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Neural tube defect,152660691,OT,,,,,,,,,152660691,1,HIV infection
15266106,152661061,1,I,,20180801,20180810,20180810,EXP,,BW-GILEAD-2018-0355047,GILEAD,"ZASH R, HOLMES L, MAKHEMA J, DISEKO M, JACOBSON D, MAYONDI G, MMALANE M, MOFENSON L, GAOLATHE T, PETLO C, ESSEX M, LOCKMAN S, SHAPIRO R. SURVEILLANCE FOR NEURAL TUBE DEFECTS FOLLOWING ANTIRETROVIRAL EXPOSURE FROM CONCEPTION. AIDS 2018 CONFERENCE. 2018?UNK:1?25",,,I,,Y,,,20180810,,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Neural tube defect,152661061,OT,,,,,,,,,152661061,1,HIV infection
15266110,152661101,1,I,,20180801,20180810,20180810,EXP,,BW-GILEAD-2018-0355048,GILEAD,"ZASH R, HOLMES L, MAKHEMA J, DISEKO M, JACOBSON D, MAYONDI G, MMALANE M, MOFENSON L, GAOLATHE T, PETLO C, ESSEX M, LOCKMAN S, SHAPIRO R. SURVEILLANCE FOR NEURAL TUBE DEFECTS FOLLOWING ANTIRETROVIRAL EXPOSURE FROM CONCEPTION. AIDS 2018 CONFERENCE. 2018?UNK:1?25",,,I,,Y,,,20180810,,OT,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Neural tube defect,152661101,OT,,,,,,,,,152661101,1,HIV infection
15266655,152666551,1,I,20180706,20180803,20180810,20180810,EXP,,US-PFIZER INC-2018319211,PFIZER,,47,YR,,M,Y,40,KG,20180810,,OT,US,US,EFAVIRENZ.,Electrocardiogram QT prolonged,152666551,OT,,,152666551,1,20180309,20180706,,,152666551,1,Tuberculosis
15268184,152681841,1,I,20180725,,20180725,20180725,DIR,,,FDA-CTU,,32,YR,,M,N,,,20180725,N,PH,US,US,SUSTIVA,Diarrhoea,,,152681841,HP,152681841,1,20160725,20180725,,,,,
15269007,152690071,1,I,,20180801,20180813,20180813,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-181019,RANBAXY,"BRAVO I, ALVAREZ H, MARINO A, CLOTET B, MOLTO J. RECURRENT CORONARY DISEASE IN HIV?INFECTED PATIENTS: ROLE OF DRUG?DRUG INTERACTIONS. BR J CLIN PHARMACOL. 2018?MAR? 84(7):1617?1619",39,YR,,M,Y,,,20180813,,OT,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Drug interaction;Vascular stent thrombosis,152690071,HO,,,,,,,,,152690071,1,Product used for unknown indication
15273708,152737081,1,I,,20180805,20180813,20180813,EXP,,US-GILEAD-2018-0354858,GILEAD,"TSO FY, KANG G, KWON EH, JULIUS P, LI Q, WEST JT, WOOD C. BRAIN IS A POTENTIAL SANCTUARY FOR SUBTYPE C HIV?1 IRRESPECTIVE OF ART TREATMENT OUTCOME. PLOS ONE. 13 (7) (NO PAGINATION), 2018. ARTICLE NUMBER: E0201325.. 2018?UNK:1?12",40,YR,A,M,Y,,,20180813,,OT,US,ZM,EFAVIRENZ.,Treatment failure,152737081,DE,,,,,,,,,152737081,1,HIV infection
15273723,152737231,1,I,,20180805,20180813,20180813,EXP,,US-GILEAD-2018-0355932,GILEAD,"TSO FY, KANG G, KWON EH, JULIUS P, LI Q, WEST JT, WOOD C. BRAIN IS A POTENTIAL SANCTUARY FOR SUBTYPE C HIV?1 IRRESPECTIVE OF ART TREATMENT OUTCOME. PLOS ONE. 13 (7) (NO PAGINATION), 2018. ARTICLE NUMBER: E0201325.. 2018?UNK:1?12 DOI:10.1371",34,YR,A,F,Y,,,20180813,,OT,US,ZM,EFAVIRENZ.,Treatment failure,152737231,DE,,,,,,,,,152737231,1,HIV infection
15275417,152754171,1,I,,20080612,20180814,20180814,PER,,US-009507513-0905USA03772,MERCK,,35,YR,,F,Y,,,20180814,,CN,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy;No adverse event,,,,,,,,,,,,,
15276721,152767211,1,I,200805,20180808,20180814,20180814,EXP,GB-MHRA-ADR 20276241,GB-009507513-1808GBR003583,MERCK,,32,YR,,F,Y,,,20180814,,MD,GB,GB,EFAVIRENZ.,Drug ineffective;Drug interaction;Pregnancy with implant contraceptive,152767211,OT,,,152767211,2,2006,,,,152767211,1,HIV test
15277256,152772561,1,I,,20110607,20180814,20180814,EXP,,GB-GILEAD-2011-0040557,GILEAD,,31,YR,A,F,Y,,,20180814,,CN,GB,GB,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,152772561,OT,,,,,,,,,152772561,1,HIV infection
15281164,152811641,1,I,,20180806,20180815,20180815,EXP,,GB-TEVA-2018-GB-940058,TEVA,,54,YR,,M,Y,,,20180815,,CN,GB,GB,EFAVIRENZ.,Anal fistula infection,152811641,OT,,,,,,,,,152811641,1,HIV infection
15283073,152830731,1,I,20180730,,20180731,20180731,DIR,,,FDA-CTU,,63,YR,,M,N,,,20180730,N,PH,US,US,EFAVIRENZ.,Fall;Laceration,,,152830731,HP,152830731,1,20030110,,,,152830731,1,HIV test positive
15287323,152873232,2,F,,20180831,20180817,20180914,EXP,,PT-AUROBINDO-AUR-APL-2018-041849,AUROBINDO,,,,,,Y,,,20180914,,OT,PT,PT,EFAVIRENZ.,Hepatitis B reactivation;Neuropsychiatric symptoms,152873232,OT,,,152873232,1,2014,,,,152873232,1,Antiretroviral therapy
15288442,152884423,3,F,2008,20180914,20180817,20180914,EXP,,GB-009507513-2008-179999-NL,MERCK,,,,,F,Y,71,KG,20180914,,CN,US,GB,EFAVIRENZ.;SUSTIVA,Labelled drug-drug interaction medication error;Normal newborn;Pregnancy with implant contraceptive,152884423,OT,,,152884423,1,20040811,20070716,,,152884423,1,Contraception
15290927,152909271,1,I,2014,20180810,20180817,20180817,EXP,,ES-BAUSCH-BL-2018-022316,BAUSCH AND LOMB,"BRAVO I, ALVAREZ H, MARINO A, CLOTET B, MOLTO I. RECURRENT CORONARY DISEASE IN HIV?INFECTED PATIENTS: ROLE OF DRUG?DRUG INTERACTIONS.. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY.. 2018?84(7):1617?1619.",39,YR,,M,Y,,,20180817,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,152909271,HO,,,152909271,1,2014,,,,152909271,1,Product used for unknown indication
15291772,152917721,1,I,20180619,20180813,20180817,20180817,EXP,GB-MHRA-EYC 00183472,GB-GILEAD-2018-0356331,GILEAD,,62,YR,A,M,Y,75,KG,20180817,,MD,GB,GB,EFAVIRENZ.,Breast swelling;Breast tenderness;Gynaecomastia,152917721,OT,,,152917721,1,20180614,,,,152917721,1,HIV infection
15296122,152961221,1,I,,20180806,20180820,20180820,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-073457,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20180820,,MD,GB,GB,EFAVIRENZ.,Renal impairment,152961221,OT,,,152961221,1,201611,,,,152961221,1,HIV infection
15296312,152963122,2,F,,20180814,20180820,20180921,EXP,,US-VIIV HEALTHCARE LIMITED-US2018149371,VIIV,"MICHAL JL, RAB S, PATEL M, KYLE AW, MILLER LS, EASLEY KA ET.ALL. INCIDENCE OF ACUTE KIDNEY INJURY IN PATIENTS COINFECTED WITH HIV AND HEPATITIS C VIRUS RECEIVING TENOFOVIR DISOPROXIL FUMARATE AND LEDIPASVIR/SOFOSBUVIR IN A REAL?WORLD, URBAN, RYAN WHITE CLINIC. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2018?34(8):690?698.DOI:10.1089/AID.2017.0271",47,YR,,M,Y,,,20180921,,OT,US,US,EFAVIRENZ.,Acute kidney injury,152963122,OT,,,,,,,,,152963122,1,Antiretroviral therapy
15297669,152976691,1,I,,20180816,20180820,20180820,EXP,,TW-GILEAD-2018-0357319,GILEAD,,40,YR,A,F,Y,,,20180820,,MD,TW,TW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypersensitivity;Insomnia;Osteoporosis,152976691,OT,,,,,,,,,152976691,1,HIV infection
15299845,152998452,2,F,,20180813,20180821,20180827,EXP,,US-HETERO CORPORATE-HET2018US00806,HETERO,"SHAIKH B, SOHAIB M, ALSHANTTI R, BARRERA F, MURVELASHVILI N.. A FAST END TO A SLOW DISEASE.. J?CLIN?TRANSL?ENDOCRINOL?CASE?REP. 2018?9?11",50,YR,,M,Y,,,20180823,,OT,US,US,Efavirenz+Emtricitabine+Tenofovir,Myxoedema coma,152998452,OT,,,,,,,,,152998452,1,HIV infection
15307026,153070261,1,I,20180720,20180814,20180822,20180822,EXP,,ZA-MYLANLABS-2018M1062941,MYLAN,,27,YR,,M,Y,,,20180822,,OT,ZA,ZA,EFAVIRENZ.,Acute kidney injury;Coma scale abnormal;Dyspnoea;General physical health deterioration,153070261,OT,,,153070261,1,20180604,20180721,,,153070261,1,Antiretroviral therapy
15308160,153081601,1,I,20171006,20180810,20180822,20180822,EXP,,PHHY2018GB072950,SANDOZ,,43,YR,,F,Y,,,20180822,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,153081601,OT,,,,,,,,,153081601,1,Product used for unknown indication
15309218,153092181,1,I,20180810,20180810,20180823,20180823,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-075558,BRISTOL MYERS SQUIBB,,63,YR,,M,Y,,,20180823,,PH,CA,CA,SUSTIVA,Constipation,153092181,HO,,,,,,,,,153092181,1,HIV infection
15311256,153112561,1,I,,20180810,20180823,20180823,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-075522,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20180823,,CN,US,US,SUSTIVA,Confusional state,,,,,,,,,,,153112561,1,Product used for unknown indication
15312442,153124421,1,I,1999,20010710,20180823,20180823,EXP,,US-VIIV HEALTHCARE LIMITED-A0153857A,VIIV,,,,,M,Y,,,20180823,,OT,NG,US,EFAVIRENZ.,Condition aggravated;Deafness bilateral;Ototoxicity;Tinnitus,153124421,OT,,,153124421,1,199810,1999,,,153124421,1,HIV infection
15312447,153124471,1,I,1999,20010710,20180823,20180823,EXP,,US-GLAXOSMITHKLINE-A0153857A,GLAXOSMITHKLINE,,,,,M,Y,,,20180823,,OT,NG,US,EFAVIRENZ.,Condition aggravated;Deafness bilateral;Ototoxicity;Tinnitus,153124471,OT,,,153124471,1,199810,1999,,,153124471,1,HIV infection
15315493,153154931,1,I,20180801,,20180815,20180815,DIR,,,FDA-CTU,,49,YR,,M,N,,,20180815,N,PH,US,US,SUSTIVA,Mental disorder,,,153154931,HP,153154931,1,,,7,YR,,,
15315747,153157471,1,I,,20170227,20180824,20180824,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2017GSK203984,VIIV,ISAH O.A. LAMIVUDINE AND HEARING LOSS. WHO PHARMACEUTICALS NEWSLETTER. 2017?1:23?28,47,YR,,M,Y,,,20180824,,OT,NG,NG,EFAVIRENZ.,Deafness;Ototoxicity,153157471,OT,,,,,,,,,153157471,1,Product used for unknown indication
15315753,153157531,1,I,,20170227,20180824,20180824,EXP,,NG-GLAXOSMITHKLINE-NG2017GSK203984,GLAXOSMITHKLINE,ISAH O.A. LAMIVUDINE AND HEARING LOSS. WHO PHARMACEUTICALS NEWSLETTER. 2017?1:23?28,47,YR,,M,Y,,,20180824,,OT,NG,NG,EFAVIRENZ.,Deafness;Ototoxicity,153157531,OT,,,,,,,,,153157531,1,Product used for unknown indication
15317955,153179553,3,F,20150608,20180815,20180824,20180824,EXP,,PHHY2018FR017047,NOVARTIS,,37,YR,,F,Y,,,20180825,,OT,FR,FR,SUSTIVA,Exposure during pregnancy;Foetal growth restriction;Live birth,153179553,OT,,,153179553,5,20150608,20150608,,,153179553,1,Product used for unknown indication
15321890,153218901,1,I,,20180816,20180827,20180827,EXP,,RO-MYLANLABS-2018M1063114,MYLAN,"BLAGA I?C, STOICA NL, DADALAU AT, POPESCU G, ABAGIU A. TUBERCULOUS MENINGITIS IN HIV PATIENT, DEVELOPED DURING APPARENTLY EFFCIENT TREATMENT FOR PULMONARY TUBERCULOSIS. CLUJUL?MED 2016?89 (SUPPL. 3):S75.",27,YR,,,Y,,,20180827,,OT,RO,RO,EFAVIRENZ.,Drug resistance;Meningitis tuberculous,153218901,OT,,,,,,,,,153218901,1,Acquired immunodeficiency syndrome
15324302,153243021,1,I,,20180813,20180828,20180828,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-078376,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180828,,OT,AU,GB,EFAVIRENZ.,Completed suicide,153243021,OT,,,,,,,,,153243021,1,Antiretroviral therapy
15325503,153255031,1,I,20180822,,20180822,20180822,DIR,,,FDA-CTU,,53,YR,,M,N,,,20180822,N,PH,US,US,EFAVIRENZ TAB,Fatigue,,,153255031,HP,153255031,1,,,1,YR,,,
15330805,153308052,2,F,,20180824,20180829,20180906,EXP,,BR-MYLANLABS-2018M1063732,MYLAN,,,,,M,Y,3.52,KG,20180906,,OT,BR,BR,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Foetal exposure during pregnancy;Hydrocele,153308052,OT,,,153308052,1,20150601,,,,153308052,1,HIV infection
15331628,153316281,1,I,,20180820,20180829,20180829,EXP,,"US-TOLMAR, INC.-TOLG20180474",TOLMAR,"ALI M, KOORAGAYALO S, MBA B, OLSEN F. ISOLATED MYOPATHY: AN UNUSUAL MANIFESTATION OF INHALED FLUTICASONE PROPIONATE AND RITONAVIR INTERACTION. ARCH BRONCONEUMOL. 2017?.",58,YR,,M,Y,,,20180829,,OT,US,US,EFAVIRENZ.,Asthenia;Drug interaction;Fall;Muscular weakness;Myopathy,153316281,HO,,,,,,,,,153316281,1,Chronic obstructive pulmonary disease
15335288,153352881,1,I,,20180110,20180830,20180830,EXP,,PHHY2017DE198990,SANDOZ,,28,YR,,M,Y,,,20180830,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,153352881,OT,,,,,,,,,153352881,1,Product used for unknown indication
15335320,153353201,1,I,,20180819,20180830,20180830,EXP,,PHHY2009FR075292,SANDOZ,,,,N,,Y,,,20180830,,OT,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,153353201,OT,,,153353201,1,20050523,20050908,,,153353201,1,Foetal exposure during pregnancy
15337817,153378171,1,I,,20151028,20180831,20180831,EXP,,ZA-009507513-1510ZAF015311,MERCK,,,,,F,Y,,,20180831,,CN,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Off label use;Pregnancy with implant contraceptive,153378171,OT,,,153378171,2,201403,,,,153378171,1,Antiretroviral therapy
15338183,153381832,2,F,20050820,20180823,20180831,20180906,EXP,,GB-009507513-2007-165356-NL,MERCK,,23,YR,,F,Y,,,20180906,,CN,GB,GB,EFAVIRENZ.,Amenorrhoea;Drug interaction;Ectopic pregnancy;Pregnancy with implant contraceptive,153381832,OT,,,153381832,1,200302,,,,153381832,1,Contraception
15338844,153388441,1,I,2018,20180829,20180831,20180831,EXP,,HT-JNJFOC-20180841091,JANSSEN,,,,A,F,Y,60,KG,20180831,,OT,HT,HT,EFAVIRENZ.,Anaemia;Extrasystoles;Hypokalaemia;Tachyarrhythmia,153388441,LT,,,153388441,1,20180622,20180720,,,153388441,1,Tuberculosis
15341650,153416502,2,F,,20180827,20180901,20180910,EXP,,US-AUROBINDO-AUR-APL-2018-043353,AUROBINDO,,50,YR,,M,Y,,,20180910,,OT,US,US,EFAVIRENZ.,Bradycardia;Cardiac arrest;Electrocardiogram QT prolonged;Hypothermia;Myxoedema coma;Unresponsive to stimuli;Ventricular arrhythmia,153416502,HO,,,,,,,,,153416502,1,Antiretroviral therapy
15343799,153437991,1,I,,20160809,20180903,20180903,EXP,,ZA-AUROBINDO-AUR-APL-2016-10805,AUROBINDO,,43,YR,,F,Y,,,20180903,,OT,ZA,ZA,EFAVIRENZ.,Autoimmune hepatitis;Hepatic enzyme abnormal;Immune reconstitution inflammatory syndrome,153437991,OT,,,,,,,,,153437991,1,HIV infection
15346868,153468681,1,I,,20180821,20180904,20180904,EXP,,GB-AUROBINDO-AUR-APL-2018-043972,AUROBINDO,,,,A,,Y,,,20180904,,MD,GB,GB,SUSTIVA,Virologic failure,153468681,OT,,,,,,,,,153468681,1,HIV infection
15348259,153482591,1,I,,20180830,20180904,20180904,EXP,FR-AFSSAPS-ST20181160,FR-GLAXOSMITHKLINE-FR2018158242,GLAXOSMITHKLINE,,40,YR,,M,Y,,,20180904,,MD,FR,FR,SUSTIVA,Lipodystrophy acquired,153482591,OT,,,153482591,1,19990412,20050512,,,153482591,1,HIV infection
15348740,153487401,1,I,,20180830,20180904,20180904,EXP,FR-AFSSAPS-ST20181160,FR-VIIV HEALTHCARE LIMITED-FR2018158242,VIIV,,40,YR,,M,Y,,,20180904,,MD,FR,FR,SUSTIVA,Lipodystrophy acquired,153487401,OT,,,153487401,1,19990412,20050512,,,153487401,1,HIV infection
15350485,153504852,2,F,,20180914,20180905,20180917,EXP,,UG-HETERO CORPORATE-HET2018UG00862,HETERO,,,,,,Y,,,20180917,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,153504852,CA,,,153504852,1,20180510,,,,153504852,1,HIV infection
15352114,153521141,1,I,,20180830,20180905,20180905,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2018157536,VIIV,CASTRO RS. HEPATITIS B REACTIVATION AFTER HCV TREATMENT WITH SOFOSBUVIR/LEDIPASVIR IN A HIV?COINFECTED PATIENT WITH PREVIOUS POSITIVE ANTI?HBS ANTIBODY: A CASE REPORT AND A REVIEW OF LITERATURE. HIV + AIDS REVIEW. 2018?17 (2):146?151,54,YR,,M,Y,,,20180905,,OT,PT,PT,EFAVIRENZ.,Neuropsychiatric symptoms,153521141,OT,,,,,,,,,153521141,1,Chronic hepatitis C
15352438,153524381,1,I,,20180830,20180905,20180905,EXP,,PT-GLAXOSMITHKLINE-PT2018157536,GLAXOSMITHKLINE,CASTRO RS. HEPATITIS B REACTIVATION AFTER HCV TREATMENT WITH SOFOSBUVIR/LEDIPASVIR IN A HIV?COINFECTED PATIENT WITH PREVIOUS POSITIVE ANTI?HBS ANTIBODY: A CASE REPORT AND A REVIEW OF LITERATURE. HIV + AIDS REVIEW. 2018?17 (2):146?151,54,YR,,M,Y,,,20180905,,OT,PT,PT,EFAVIRENZ.,Neuropsychiatric symptoms,153524381,OT,,,,,,,,,153524381,1,Chronic hepatitis C
15356633,153566331,1,I,20180830,,20180830,20180830,DIR,,,FDA-CTU,,61,YR,,M,N,,,20180830,N,PH,US,US,EFAVIRENZ TAB,Bone loss,,,153566331,HP,153566331,1,20170127,,,,,,
15357154,153571541,1,I,20180830,,20180830,20180830,DIR,,,FDA-CTU,,61,YR,,M,N,,,20180830,N,PH,US,US,efavirenz/sustiva,Bone loss,,,153571541,HP,153571541,1,20170127,,,,,,
15357253,153572531,1,I,20060216,20180901,20180906,20180906,EXP,,FR-ABBVIE-18S-056-2474150-00,ABBVIE,,25,YR,,F,Y,,,20180906,,OT,FR,FR,SUSTIVA,Abortion induced;Exposure during pregnancy;Insomnia;Vertigo,153572531,HO,,,153572531,1,20050908,20050908,,,153572531,1,HIV infection
15357443,153574431,1,I,20171006,20180828,20180906,20180906,EXP,GB-EMA-DD-20180827-ASHWINIHVP-120514,GB-NOVOPROD-619477,NOVO NORDISK,,43,YR,A,F,Y,,,20180906,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,153574431,OT,,,153574431,7,20171006,,,,153574431,1,Product used for unknown indication
15357909,153579091,1,I,20171006,20180819,20180906,20180906,EXP,,PHHY2018GB086977,SANDOZ,,43,YR,,F,Y,,,20180906,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,153579091,OT,,,153579091,4,20171006,20180205,,,153579091,1,Product used for unknown indication
15357967,153579671,1,I,,20180831,20180906,20180906,EXP,,UG-MYLANLABS-2018M1065596,MYLAN,,,,I,F,Y,3.6,KG,20180906,,OT,UG,UG,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,153579671,OT,,,153579671,1,20180510,,,,153579671,1,HIV infection
15361880,153618802,2,F,20171006,20180830,20180907,20180911,EXP,,PHHY2018GB085930,SANDOZ,,,,,M,Y,,,20180912,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,153618802,DE,,,153618802,2,20171006,20180205,,,153618802,1,Foetal exposure during pregnancy
15362806,153628061,1,I,,20180827,20180907,20180907,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-081824,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,,,20180907,,OT,US,US,EFAVIRENZ.,Basedow's disease;Immune reconstitution inflammatory syndrome,153628061,OT,,,,,,,,,153628061,1,HIV infection
15362898,153628981,1,I,,20180827,20180907,20180907,EXP,,ID-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-081902,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20180907,,OT,ID,US,EFAVIRENZ.,Basedow's disease;Immune reconstitution inflammatory syndrome;Maternal exposure during pregnancy;Normal newborn;Product use issue,153628981,OT,,,,,,,,,153628981,1,HIV infection
15363025,153630251,1,I,20171006,20180828,20180907,20180907,EXP,GB-EMA-DD-20180827-KSEVHUMANWT-125137,GB-NOVOPROD-619421,NOVO NORDISK,,,,,M,Y,,,20180907,,CN,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,153630251,OT,,,153630251,2,20171006,20180205,,,153630251,1,Product used for unknown indication
15363718,153637181,1,I,,20150610,20180907,20180907,PER,,US-009507513-1506USA007010,MERCK,,33,YR,,F,Y,,,20180907,,CN,US,US,efavirenz (+) emtricitabine (+) tenofovir disoproxil fumarate,Maternal exposure during pregnancy;No adverse event,,,,,,,,,,,,,
15366222,153662221,1,I,20090930,20180904,20180910,20180910,EXP,FR-EMA-20130214-MMEVHUMANWT-150034270,FR-ABBVIE-18S-056-2473844-00,ABBVIE,,,,,F,Y,,,20180910,,CN,FR,FR,SUSTIVA,Drug ineffective;Drug interaction;Exposure during pregnancy;Normal newborn;Pregnancy on contraceptive;Unintended pregnancy,153662221,OT,,,153662221,2,20080727,,,,153662221,1,Product used for unknown indication
15367987,153679872,2,F,20180630,20180829,20180910,20180912,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2018GSK156040,VIIV,,39,YR,,F,Y,49,KG,20180912,,MD,CN,CN,EFAVIRENZ.,Hypersensitivity;Liver injury,153679872,HO,,,153679872,1,20180621,20180712,,,153679872,1,HIV infection
15370793,153707931,1,I,20171006,20180910,20180911,20180911,EXP,,GB-TEVA-2018-GB-953327,TEVA,,,,,M,Y,,,20180911,,CN,GB,GB,Efavirenz Film?coated Tablet,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,153707931,OT,,,153707931,1,20171006,20180205,,,153707931,1,Product used for unknown indication
15375863,153758631,1,I,20171006,20180910,20180912,20180912,EXP,GB-EMA-DD-20180827-ASHWINIHVP-120514,GB-TEVA-2018-GB-954133,TEVA,,43,YR,,F,Y,,,20180912,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,153758631,OT,,,,,,,,,153758631,1,HIV infection
15376017,153760171,1,I,,20180906,20180912,20180912,EXP,,US-GILEAD-2018-0361988,GILEAD,,37,YR,A,M,Y,,,20180912,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal disorder,153760171,HO,,,153760171,1,20150429,,,,153760171,1,HIV infection
15383786,153837861,1,I,,20180705,20180913,20180913,EXP,,IE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063019,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20180913,,OT,IE,IE,EFAVIRENZ.,No adverse event,153837861,OT,,,153837861,1,20180620,20180814,,,153837861,1,HIV infection
15386725,153867251,1,I,2014,20180717,20180914,20180914,EXP,,PHHY2018ES049784,SANDOZ,,39,YR,,M,Y,,,20180914,,OT,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,153867251,OT,,,,,,,,,153867251,1,HIV infection
15387938,153879381,1,I,,20180831,20180915,20180915,EXP,,GB-AUROBINDO-AUR-APL-2018-045413,AUROBINDO,,,,A,,Y,,,20180915,,MD,GB,GB,SUSTIVA,Virologic failure,153879381,OT,,,,,,,,,153879381,1,HIV infection
15388140,153881402,2,F,,20180911,20180915,20180924,EXP,,UG-AUROBINDO-AUR-APL-2018-045363,AUROBINDO,,,,,F,Y,3.6,KG,20180924,,OT,UG,UG,EFAVIRENZ.,Polydactyly,153881402,CA,,,153881402,1,20180510,,,,153881402,1,HIV infection
15388155,153881552,2,F,20171006,20180907,20180915,20180921,EXP,,GB-AUROBINDO-AUR-APL-2018-045705,AUROBINDO,,43,YR,,F,Y,,,20180921,,CN,GB,GB,Efavirenz Film?coated Tablet,Abortion spontaneous;Exposure during pregnancy,153881552,OT,,,153881552,5,20171006,20180205,,,153881552,1,Product used for unknown indication
15389945,153899451,1,I,,20180911,20180917,20180917,EXP,,IN-STRIDES ARCOLAB LIMITED-2018SP007787,STRIDES,,,,,,Y,,,20180917,,OT,IN,IN,EFAVIRENZ.,Nephropathy toxic,153899451,OT,,,,,,,,,153899451,1,HIV infection
15391496,153914961,1,I,,20180904,20180917,20180917,EXP,,PHHY2018DE092924,SANDOZ,,,,,,Y,,,20180917,,OT,DE,DE,EFAVIRENZ.,Abdominal pain;Acute kidney injury;Anaemia;Anal cancer;Arthralgia;Blood creatinine increased;Calculus urinary;Circulatory collapse;Clostridium difficile colitis;Dehydration;Dermatitis allergic;Diarrhoea;Drug withdrawal syndrome;Dyspnoea;Erysipelas;Fatigue;Fluid overload;Gastrointestinal disorder;Gastrointestinal infection;General physical health deterioration;Haemorrhoidal haemorrhage;Headache;Hepatic encephalopathy;Hepatic failure;Hepatobiliary disease;Hepatocellular carcinoma;Hypersensitivity vasculitis;Hypertension;Hyponatraemia;Infection;Lactic acidosis;Liver disorder;Lymphoedema;Mental disorder;Myocardial infarction;Nausea;Neoplasm;Neutropenia;Pancreatitis acute;Pancytopenia;Peritonitis bacterial;Portal vein thrombosis;Sleep disorder;Soft tissue infection;Somnolence;Streptococcal sepsis;Vertigo,153914961,OT,,,,,,,,,153914961,1,Chronic hepatitis C
15397944,153979441,1,I,,20180907,20180918,20180918,EXP,,ES-GILEAD-2018-0362550,GILEAD,"ALVAREZ H, MARINO A, VALCARCE N, GARCIA?GONZALEZ J, DIAZ?CAMBRE H, LLIBRE JM. OVERDOSE OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN AN HIV?1?INFECTED SUBJECT WITH ATTEMPTED SUICIDE. INFECTION. 2018?UNK:UNK",51,YR,A,M,Y,,,20180918,,OT,ES,ES,EFAVIRENZ.,Hypophosphataemia;Osteopenia;Vitamin D deficiency,153979441,OT,,,153979441,1,2012,,,,153979441,1,HIV infection
15398444,153984441,1,I,2002,20180914,20180918,20180918,EXP,,PT-MYLANLABS-2018M1068194,MYLAN,"MARTINS S, QUINAZ C, XARA S, VASCONCELOS O, VICENTE P, SARMENTO?CASTRO R.. AIDS ? RELATED PRIMARY PULMONARY LYMPHOMA.. REVISTA PORTUGUESA DE DOENCAS INFECCIOSAS.. 2017?13 (3):142?5",55,YR,,M,Y,,,20180917,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,153984441,DE,,,,,,,,,153984441,1,HIV infection
15405189,154051891,1,I,,20180605,20180920,20180920,PER,,US-LAURUS LABS LIMITED-201800046,LAURUS LABS LIMITED,SHARMA AV. DRUG?DRUG INTERACTION LEADING TO FANCONI^S SYNDROME IN A GERIATRIC PATIENT. J?AM?GERIATR?SOC . 2018?66 (SUPPL 2)S17:,73,YR,,M,Y,,,20180911,,OT,US,US,EFAVIRENZ.,Chest pain;Drug interaction;Fanconi syndrome acquired;Nausea;Vomiting,154051891,OT,,,,,,,,,154051891,1,HIV infection
15405233,154052331,1,I,,20180709,20180920,20180920,PER,,US-LAURUS LABS LIMITED-201800105,LAURUS LABS LIMITED,BHOGAL S. TENOFOVIR?INDUCED FANCONI SYNDROME PRESENTING AS HYPOKALEMIC PERIODIC PARALYSIS. AMJ?THER 2017?24(5):E617?E618.,54,YR,,F,Y,,,20180911,,OT,US,US,EFAVIRENZ.,Fall;Fanconi syndrome acquired;Muscular weakness,154052331,OT,,,,,,,,,154052331,1,HIV infection
15408626,154086262,2,F,20180627,20180914,20180920,20180920,EXP,,PHHY2018LS101573,NOVARTIS,,38,YR,,M,Y,56,KG,20180920,,CN,LS,LS,EFAVIRENZ.,Liver function test increased,154086262,HO,,,154086262,1,20180409,20180822,,,154086262,1,Tuberculosis
15410705,154107051,1,I,,20180917,20180921,20180921,EXP,,GB-009507513-1809GBR008459,MERCK,,,,E,M,Y,,,20180921,,CN,GB,GB,EFAVIRENZ.,Death,154107051,DE,,,,,,,,,,,
15411866,154118661,1,I,20180627,20180903,20180921,20180921,PER,,US-JNJFOC-20180902500,JANSSEN,,38,YR,A,M,Y,56,KG,20180921,,OT,US,US,EFAVIRENZ.,Liver function test abnormal,154118661,HO,,,154118661,1,20180409,20180822,,,154118661,1,Tuberculosis
15418970,154189701,1,I,,20180919,20180924,20180924,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-087430,BRISTOL MYERS SQUIBB,,,,,M,Y,74.83,KG,20180924,,CN,US,US,SUSTIVA,Drug screen positive,,,,,154189701,1,1998,,,,154189701,1,HIV infection
15419057,154190571,1,I,,20180828,20180924,20180924,EXP,,RO-VIIV HEALTHCARE LIMITED-RO2018155512,VIIV,"BLAGA I?C, STOICA NL, DADALAU AT, POPESCU G, ABAGIU A. TUBERCULOUS MENINGITIS IN HIV PATIENT, DEVELOPED DURING APPARENTLY EFFCIENT TREATMENT FOR PULMONARY TUBERCULOSIS. CLUJUL MEDICAL. 2016?89:75",27,YR,,,Y,,,20180924,,,COUNTRY NOT SPECIFIED,RO,EFAVIRENZ.,Drug resistance;Meningitis tuberculous,154190571,OT,,,,,,,,,154190571,1,Acquired immunodeficiency syndrome
15419067,154190671,1,I,,20180828,20180924,20180924,EXP,,RO-GLAXOSMITHKLINE-RO2018155512,GLAXOSMITHKLINE,"BLAGA I?C, STOICA NL, DADALAU AT, POPESCU G, ABAGIU A. TUBERCULOUS MENINGITIS IN HIV PATIENT, DEVELOPED DURING APPARENTLY EFFCIENT TREATMENT FOR PULMONARY TUBERCULOSIS. CLUJUL MEDICAL. 2016?89:75",27,YR,,,Y,,,20180924,,,COUNTRY NOT SPECIFIED,RO,EFAVIRENZ.,Drug resistance;Meningitis tuberculous,154190671,OT,,,,,,,,,154190671,1,Acquired immunodeficiency syndrome
15419136,154191361,1,I,200109,20180919,20180924,20180924,EXP,,FR-GLAXOSMITHKLINE-FR2018172212,GLAXOSMITHKLINE,"UNAL G, MOUREZ T, LEOZ M, ALESSANDRI?GRADT E, GUILLOU?GUILLEMETTE HL, CHENNEBAULT JM ET AL. FIRST REPORT OF TRANSMISSION OF A HIGHLY RESISTANT STRAIN OF HIV?1 GROUP O. AIDS. 2016?30(16):2565?2568. DOI: 10.1097/QAD.0000000000001253.",,,,F,Y,,,20180924,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,154191361,OT,,,,,,,,,154191361,1,HIV infection
15419142,154191421,1,I,200109,20180919,20180924,20180924,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018172212,VIIV,"UNAL G, MOUREZ T, LEOZ M, ALESSANDRI?GRADT E, GUILLOU?GUILLEMETTE HL, CHENNEBAULT JM ET AL. FIRST REPORT OF TRANSMISSION OF A HIGHLY RESISTANT STRAIN OF HIV?1 GROUP O. AIDS. 2016?30(16):2565?2568. DOI: 10.1097/QAD.0000000000001253.",,,,F,Y,,,20180924,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,154191421,OT,,,,,,,,,154191421,1,HIV infection
15420891,154208911,1,I,20171209,20180919,20180924,20180924,EXP,,ZW-GILEAD-2018-0364724,GILEAD,,33,YR,A,F,Y,,,20180924,,OT,ZW,ZW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,154208911,OT,,,154208911,1,20151015,,,,154208911,1,HIV infection
15423369,154233691,1,I,,20180919,20180925,20180925,PER,,US-GILEAD-2018-0364520,GILEAD,,65,YR,E,M,Y,,,20180925,,CN,US,US,EFAVIRENZ.,Vomiting,,,,,,,,,,,154233691,1,HIV infection
15424004,154240041,1,I,20171209,20180919,20180925,20180925,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2018173230,VIIV,,33,YR,,F,Y,,,20180925,,OT,ZW,ZW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,154240041,OT,,,154240041,1,20151015,,,,154240041,1,HIV infection
15424034,154240341,1,I,20171209,20180919,20180925,20180925,EXP,,ZW-GLAXOSMITHKLINE-ZW2018173230,GLAXOSMITHKLINE,,33,YR,,F,Y,,,20180925,,OT,ZW,ZW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,154240341,OT,,,154240341,1,20151015,,,,154240341,1,HIV infection
15427316,154273161,1,I,,20180917,20180925,20180925,PER,,CA-BIOVERATIV-2018BV000656,BIOVERATIV,,,,,M,Y,,,20180925,,CN,CA,CA,EFAVIRENZ.,Breast mass;Breast tenderness,,,,,154273161,1,20161215,,,,154273161,1,Factor VIII deficiency
15427917,154279171,1,I,,20180715,20180926,20180926,PER,,US-STRIDES ARCOLAB LIMITED-2018SP005984,STRIDES,SWINDELLS S. NEW AND NOTEWORTHY IN TUBERCULOSIS DIAGNOSTICS AND TREATMENT. TOP ANTIVIR MED. 2018?26(2):58?61,,,,,Y,,,20180926,,OT,US,US,EFAVIRENZ.,Cough;Dyspnoea;Immune reconstitution inflammatory syndrome;Pyrexia,154279171,OT,,,,,,,,,154279171,1,HIV infection
15429863,154298631,1,I,,20180921,20180926,20180926,EXP,,PHHY2018PT105712,SANDOZ,,32,YR,,M,Y,,,20180926,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154298631,LT,,,,,,,,,154298631,1,Chronic hepatitis C
15432480,154324801,1,I,,20180824,20180927,20180927,EXP,,RO-AUROBINDO-AUR-APL-2018-044439,AUROBINDO,,27,YR,,,Y,,,20180927,,OT,RO,RO,EFAVIRENZ.,Drug resistance;Meningitis tuberculous,154324801,OT,,,,,,,,,154324801,1,Acquired immunodeficiency syndrome
15433271,154332711,1,I,,20180917,20180927,20180927,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-122007,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20180927,,MD,GB,GB,EFAVIRENZ.,Renal impairment,154332711,OT,,,,,,,,,154332711,1,HIV infection
15434583,154345831,1,I,,20180924,20180927,20180927,PER,,US-GILEAD-2018-0365154,GILEAD,,42,YR,A,F,Y,,,20180927,,CN,US,US,SUSTIVA,Drug resistance,154345831,OT,,,,,,,,,154345831,1,Product used for unknown indication
15435632,154356321,1,I,,20180921,20180927,20180927,EXP,,PHHY2018PT105702,SANDOZ,,32,YR,,M,Y,,,20180927,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154356321,LT,,,,,,,,,154356321,1,HIV infection
15438011,154380111,1,I,201610,20180630,20180928,20180928,EXP,,GB-AUROBINDO-AUR-APL-2018-035836,AUROBINDO,,38,YR,,F,Y,,,20180928,,OT,GB,GB,Efavirenz Film?coated Tablet,Abortion induced;Drug interaction;Pregnancy with implant contraceptive;Unintended pregnancy,154380111,OT,,,154380111,3,201106,,,,154380111,1,HIV infection
15438733,154387331,1,I,,20180926,20180928,20180928,EXP,,UG-AUROBINDO-AUR-APL-2018-048507,AUROBINDO,,36,WK,,,Y,2.2,KG,20180928,,MD,UG,UG,EFAVIRENZ.,Ankyloglossia congenital;Foetal exposure during pregnancy,154387331,CA,,,154387331,1,20171030,,,,154387331,1,HIV infection
15439574,154395741,1,I,20180303,20180926,20180928,20180928,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP008416,STRIDES,,,,,,Y,,,20180928,,OT,UG,UG,EFAVIRENZ.,Ankyloglossia congenital;Foetal exposure during pregnancy;Low birth weight baby;Premature baby,154395741,CA,,,,,,,,,154395741,1,Product used for unknown indication
15439575,154395751,1,I,20171030,20180926,20180928,20180928,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP008415,STRIDES,,,,,,Y,,,20180928,,OT,UG,UG,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,154395751,OT,,,154395751,1,20171030,,,,154395751,1,HIV infection
15440108,154401081,1,I,20180917,,20180925,20180925,DIR,,,FDA-CTU,,73,YR,,M,N,,,20180924,N,PH,US,US,EFAVIRENZ TAB 600MG,Pruritus,,,154401081,HP,154401081,1,201801,,,,154401081,1,HIV infection
15440348,154403481,1,I,,20180924,20180928,20180928,EXP,,PHHY2018PT108602,SANDOZ,,29,YR,,M,Y,,,20180928,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154403481,LT,,,,,,,,,154403481,1,HIV infection
15441050,154410501,1,I,20180907,20180919,20180928,20180928,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-088186,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20180928,,OT,ZW,ZW,EFAVIRENZ.,Maternal exposure during pregnancy;Product use issue;Stillbirth,154410501,OT,,,154410501,1,20151015,,,,154410501,1,HIV infection
15448433,154484331,1,I,,20180918,20180929,20180929,EXP,,PT-AUROBINDO-AUR-APL-2018-047799,AUROBINDO,,32,YR,,M,Y,,,20180929,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154484331,OT,,,,,,,,,154484331,1,Hepatitis C
15450015,154500151,1,I,20180925,,20180926,20180926,DIR,,,FDA-CTU,,73,YR,,M,N,,,20180925,N,PH,US,US,EFAVIRENZ TAB 600MG,Product substitution issue;Pruritus,,,154500151,HP,154500151,1,201801,,,,,,
6927324,69273244,4,F,20050813,20180904,20090304,20180912,EXP,,FR-GILEAD-2009-0020445,GILEAD,,,,N,F,Y,1.19,KG,20180912,,MD,FR,FR,SUSTIVA,Arnold-Chiari malformation;Brain herniation;Foetal exposure during pregnancy;Foetal malformation;Spina bifida,69273244,CA,,,69273244,1,20050523,20060216,,,69273244,1,HIV infection
7117171,711717110,10,F,,20180904,20090917,20180913,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14780902,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20180913,,CN,US,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,711717110,OT,,,711717110,7,200802,,,,711717110,1,HIV infection
7230481,72304813,3,F,2008,20180821,20091224,20180823,EXP,,GB-GILEAD-2009-0026167,GILEAD,,33,YR,A,F,Y,,,20180823,,OT,GB,GB,EFAVIRENZ.,Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Normal newborn;Pregnancy with implant contraceptive,72304813,OT,,,72304813,4,20040811,20070716,,,72304813,1,HIV infection
7328578,73285785,5,F,,20180719,20100323,20180801,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15029879,BRISTOL MYERS SQUIBB,,,,,,Y,,,20180801,,OT,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Plagiocephaly,73285785,CA,,,,,,,,,73285785,1,Product used for unknown indication
7454279,74542793,3,F,20051226,20180719,20100706,20180726,EXP,,US-GILEAD-2010-0030154,GILEAD,,0,DY,,,Y,,,20180726,,OT,US,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,74542793,CA,,,,,,,,,74542793,1,HIV infection
7944305,79443052,2,F,,20180722,20110513,20180801,EXP,,PHHY2011GB39585,SANDOZ,,,,,,Y,,,20180801,,OT,GB,GB,EFAVIRENZ.,Pancytopenia;Toxicity to various agents,79443052,DE,,,,,,,,,79443052,1,Burkitt's lymphoma
8682424,86824244,4,F,20120629,20180725,20120725,20180730,EXP,,UG-PFIZER INC-2012176280,PFIZER,"POLIS, C.. PREFERENCE FOR SAYANA PRESS VERSUS INTRAMUSCULAR DEPO?PROVERA AMONG HIV?POSITIVE WOMEN IN RAKAI, UGANDA: A RANDOMIZED CROSSOVER TRIAL. CONTRACEPTION. 2013?89:385?395",23,YR,,F,Y,37.5,KG,20180730,,MD,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,86824244,DE,,,86824244,1,20120425,,,,86824244,1,Contraception
9109057,91090573,3,F,2012,20180702,20130222,20180716,EXP,,BR-VIIV HEALTHCARE LIMITED-A1012284A,VIIV,,0,YR,,F,Y,2.9,KG,20180716,,OT,BR,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,91090573,CA,,,91090573,1,20120803,20120803,,,91090573,1,Antiretroviral therapy
9124221,91242214,4,F,20120521,20180703,20130227,20180713,EXP,,US-GILEAD-2013-0070291,GILEAD,,0,YR,,F,Y,2.88,KG,20180713,,OT,BR,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital disorder female,91242214,OT,,,91242214,1,20120521,20121128,,,91242214,1,HIV infection
9167066,91670663,3,F,20121128,20180702,20130318,20180711,EXP,,BR-009507513-1302BRA013086,MERCK,,,,,F,Y,2.88,KG,20180711,,CN,US,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,91670663,OT,,,91670663,1,20120803,20120611,,,91670663,1,Product used for unknown indication
9823287,98232873,3,F,,20180614,20140116,20180723,PER,,US-009507513-1401USA003256,MERCK,,31,YR,,F,Y,,,20180723,,OT,US,US,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy,,,,,,,,,,,98232873,1,HIV infection
